C12N

MICROORGANISMS OR ENZYMES

COMPOSITIONS THEREOF

PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS

MUTATION OR GENETIC ENGINEERING

CULTURE MEDIA microbiological testing media C12Q1/00

Attention is drawn to Notes (1) to (3) following the title of class C12.

Biocidal, pest repellant, pest attractant or plant growth regulatory activity of compounds or preparations is further classified in subclass A01P.

Therapeutic activity of single-cell proteins or enzymes is further classified in subclass A61P.

When classifying in this subclass, classification is also made in group B01D15/08 insofar as subject matter of general interest relating to chromatography is concerned.

In this subclass, it is desirable to add the indexing codes of subclass C12R.

Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N9/00 according to the peptides, with the appropriate indexing codes.

In this subclass, combination sets [C-Sets] are used. The detailed information about the C-Sets construction and the associated syntax rules is present in the definitions of C12N.

The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

C12N1/11

covered by

C12N15/79

C12N1/13

covered by

C12N15/79

C12N1/15

covered by

C12N15/80

C12N1/19

covered by

C12N15/81

C12N1/21

covered by

C12N15/74

C12N5/02

covered by C12N5/0006, C12N5/04 - C12N5/166C12N5/07 - C12N5/095 covered by

C12N5/06

C12N5/18

covered by

C12N5/16

C12N5/20

covered by

C12N5/163

C12N5/22

covered by

C12N5/16

C12N5/24

covered by

C12N5/163

C12N5/26

covered by

C12N5/166

C12N5/28

covered by

C12N5/166

C12N15/53

covered by

C12N9/0004

C12N7/01

covered by

C12N7/00

C12N9/02-C12N9/08 covered by

C12N9/0004

C12N9/26

covered by

C12N9/2408

C12N9/28-C12N9/30 covered by C12N9/2414 - C12N9/242

C12N9/32

covered by

C12N9/2422

C12N9/34

covered by

C12N9/2428

C12N9/36

covered by

C12N9/2462

C12N9/38

covered by

C12N9/2468

C12N9/40

covered by

C12N9/2465

C12N9/42

covered by

C12N9/2434

C12N9/44

covered by

C12N9/2451

C12N9/46

covered by

C12N9/2454

C12N9/56

covered by

C12N9/54

C12N9/66

covered by

C12N9/6448

C12N9/68

covered by

C12N9/6435

C12N9/70

covered by

C07K14/3153

C12N9/72

covered by

C12N9/6462

C12N9/74

covered by

C12N9/6429

C12N9/76

covered by

C12N9/6427

C12N15/05

covered by

C12N5/14

C12N15/06

covered by

C12N5/16

C12N15/07

covered by

C12N5/16

C12N15/08

covered by

C12N5/166

C12N15/12

covered by

C07K14/435

C12N15/13

covered by

C07K16/00

C12N15/14

covered by

C07K14/765

C12N15/15

covered by

C07K14/81

C12N15/16

covered by

C07K14/575

C12N15/17

covered by

C07K14/62

C12N15/18

covered by

C07K14/61

C12N15/19

covered by

C07K14/52

C12N15/20

covered by

C07K14/555

C12N15/21

covered by

C07K14/56

C12N15/22

covered by

C07K14/565

C12N15/23

covered by

C07K14/57

C12N15/24

covered by

C07K14/54

C12N15/25

covered by

C07K14/545

C12N15/26

covered by

C07K14/55

C12N15/27

covered by

C07K14/53

C12N15/28

covered by

C07K14/525

C12N15/29

covered by

C07K14/415

C12N15/30

covered by

C07K14/44

C12N15/31

covered by C07K14/195, C07K14/005

C12N15/32

covered by

C07K14/325

C12N15/33

covered by

C07K14/005

C12N15/34

covered by

C07K14/01

C12N15/35

covered by

C07K14/015

C12N15/36

covered by

C07K14/02

C12N15/37

covered by

C07K14/025

C12N15/38

covered by

C07K14/03

C12N15/39

covered by

C07K14/065

C12N15/40

covered by

C07K14/08

C12N15/41

covered by

C07K14/085

C12N15/42

covered by

C07K14/09

C12N15/43

covered by

C07K14/105

C12N15/44

covered by

C07K14/11

C12N15/45

covered by

C07K14/115

C12N15/46

covered by

C07K14/14

C12N15/47

covered by

C07K14/145

C12N15/48

covered by

C07K14/15

C12N15/49

covered by

C07K14/155

C12N15/50

covered by

C07K14/165

C12N15/51

covered by C07K14/02, C07K14/10, C07K14/18

C12N15/53

covered by

C12N9/0004

C12N15/54

covered by

C12N9/10

C12N15/55

covered by

C12N9/14

C12N15/56

covered by

C12N9/24

C12N15/57

covered by

C12N9/48

C12N15/58

covered by

C12N9/6456

C12N15/59

covered by

C12N9/6483

C12N15/60

covered by

C12N9/88

C12N15/61

covered by

C12N9/90

C12N15/83

covered by

C12N15/82

C12N15/84

covered by

C12N15/82

In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

C12N1/00

Microorganisms, e.g. protozoa

Compositions thereof medicinal preparations containing material from protozoa, bacteria or viruses A61K35/66, from algae A61K36/02, from fungi A61K36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K39/00

Processes of propagating, maintaining or preserving microorganisms or compositions thereof

Processes of preparing or isolating a composition containing a microorganism

Culture media therefor

C12N1/005

after treatment of microbial biomass not covered by C12N1/02 - C12N1/08

C12N1/02

Separating microorganisms from their culture media

C12N1/04

Preserving or maintaining viable microorganisms immobilised microorganisms C12N11/00

C12N1/06

Lysis of microorganisms

C12N1/063

of yeast

C12N1/066

by physical methods

C12N1/08

Reducing the nucleic acid content

C12N1/10

Protozoa

Culture media therefor

C12N1/105

Protozoal isolates

C12N1/12

Unicellular algae

Culture media therefor as new plants A01H13/00

C12N1/125

Unicellular algae isolates

C12N1/14

Fungi culture of mushrooms A01G18/00; as new plants A01H15/00

Culture media therefor

C12N1/145

Fungal isolates

C12N1/16

Yeasts

Culture media therefor

C12N1/165

Yeast isolates

C12N1/18

Baker's yeast

Brewer's yeast

C12N1/185

Saccharomyces isolates

C12N1/20

Bacteria

Culture media therefor

C12N1/205

Bacterial isolates

C12N1/22

Processes using, or culture media containing, cellulose or hydrolysates thereof

C12N1/24

Processes using, or culture media containing, waste sulfite liquor

C12N1/26

Processes using, or culture media containing, hydrocarbons refining of hydrocarbon oils by using microorganisms C10G32/00

C12N1/28

aliphatic

C12N1/30

having five or less carbon atoms

C12N1/32

Processes using, or culture media containing, lower alkanols, i.e. C₁ to C₆

C12N1/34

Processes using foam culture

C12N1/36

Adaptation or attenuation of cells

C12N1/38

Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors

Stimulation of growth by removal of a chemical compound C12N1/34 takes precedence

C12N3/00

Spore forming or isolating processes

C12N5/00

Undifferentiated human, animal or plant cells, e.g. cell lines

Tissues

Cultivation or maintenance thereof

Culture media therefor; plant reproduction by tissue culture techniques A01H4/00

In this group, the following words are used with the meanings indicated:

a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;

a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);

a "multipotent" cell is restricted to one lineage;

"progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly forseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

C12N5/0006

Modification of the membrane of cells, e.g. cell decoration

C12N5/0012

Cell encapsulation

C12N5/0018

Culture media for cell or tissue culture media for specific animal cell type C12N5/06

C12N5/0025

Culture media for plant cell or plant tissue culture

C12N5/0031

Serum-free culture media

This group is no longer used for the classification of new documents as from 2012-01-01. The backlog of this group is being continuously reclassified to C12N5/0037 - C12N5/0056

C12N5/0037

Serum-free medium, which may still contain naturally-sourced components

C12N5/0043

Medium free of human- or animal-derived components

C12N5/005

Protein-free medium

C12N5/0056

Xeno-free medium

C12N5/0062

General methods for three-dimensional culture

C12N5/0068

General culture methods using substrates for specific animal cell type C12N5/06

C12N5/0075

using microcarriers

C12N5/0081

Purging biological preparations of unwanted cells

C12N5/0087

Purging against subsets of blood cells, e.g. purging alloreactive T cells

C12N5/0093

Purging against cancer cells

C12N5/04

Plant cells or tissues

culture media C12N5/0025

C12N5/06

Animal cells or tissues; Human cells or tissues preservation of living cells or tissues A01N1/02

In this group, the following words are used with the meanings indicated:

a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;

a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);

a "multipotent" cell is restricted to one lineage.

"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly forseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. The last place priority rule does not apply between the subgroups of this group

C12N5/0601

Invertebrate cells or tissues, e.g. insect cells; Culture media therefor

C12N5/0602

Vertebrate cells

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

C12N5/0603

Embryonic cells production of embryos, nuclear transfer A01K67/027; Embryoid bodies

C12N5/0604

Whole embryos; Culture medium therefor

C12N5/0605

Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

C12N5/0606

Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696

C12N5/0607

Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

C12N5/0608

Germ cells production of embryos, nuclear transfer A01K67/027

C12N5/0609

Oocytes, oogonia fertilised oocytes C12N5/0604

C12N5/061

Sperm cells, spermatogonia

C12N5/0611

Primordial germ cells, e.g. embryonic germ cells [EG]

C12N5/0612

sorting of gametes, e.g. according to sex or motility

C12N5/0613

Cells from endocrine organs pancreas C12N5/0676, gonads C12N5/0681

C12N5/0614

Adrenal gland

C12N5/0615

Pineal gland

C12N5/0616

Pituitary gland

C12N5/0617

Thyroid and parathyroid glands

C12N5/0618

Cells of the nervous system

C12N5/0619

Neurons

C12N5/062

Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain

C12N5/0621

Eye cells, e.g. cornea, iris pigmented cells photoreceptors C12N5/062

C12N5/0622

Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

C12N5/0623

Stem cells

C12N5/0625

Epidermal cells, skin cells; Cells of the oral mucosa

C12N5/0626

Melanocytes

C12N5/0627

Hair cells

C12N5/0628

Hair stem cells; Hair progenitors mesenchymal stem cells from hair follicles C12N5/0666

C12N5/0629

Keratinocytes; Whole skin

C12N5/063

Kereatinocyte stem cells; Keratinocyte progenitors

C12N5/0631

Mammary cells

C12N5/0632

Cells of the oral mucosa

C12N5/0633

Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands

C12N5/0634

Cells from the blood or the immune system

Committed progenitors are classified with their progeny

C12N5/0635

B lymphocytes

C12N5/0636

T lymphocytes

C12N5/0637

Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)

C12N5/0638

Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]

C12N5/0639

Dendritic cells, e.g. Langherhans cells in the epidermis

C12N5/064

Immunosuppressive dendritic cells

C12N5/0641

Erythrocytes

C12N5/0642

Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells

C12N5/0643

Osteoclasts

C12N5/0644

Platelets; Megakaryocytes

C12N5/0645

Macrophages, e.g. Kuepfer cells in the liver; Monocytes

C12N5/0646

Natural killers cells [NK], NKT cells

C12N5/0647

Haematopoietic stem cells; Uncommitted or multipotent progenitors

C12N5/0648

Splenocytes

C12N5/065

Thymocytes

C12N5/0651

Lymph nodes

C12N5/0652

Cells of skeletal and connective tissues; Mesenchyme

C12N5/0653

Adipocytes; Adipose tissue

C12N5/0654

Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth

C12N5/0655

Chondrocytes; Cartilage

C12N5/0656

Adult fibroblasts

C12N5/0657

Cardiomyocytes; Heart cells

C12N5/0658

Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts

C12N5/0659

Satellite cells

C12N5/066

Tenocytes; Tendons, Ligaments

C12N5/0661

Smooth muscle cells

C12N5/0662

Stem cells

C12N5/0663

Bone marrow mesenchymal stem cells (BM-MSC)

C12N5/0664

Dental pulp stem cells, Dental follicle stem cells

C12N5/0665

Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood

C12N5/0666

Mesenchymal stem cells from hair follicles

C12N5/0667

Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

C12N5/0668

Mesenchymal stem cells from other natural sources

C12N5/0669

Bone marrow stromal cells; Whole bone marrow isolated stem cells from bone marrow C12N5/0647, C12N5/0663

C12N5/067

Hepatocytes

C12N5/0671

Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

C12N5/0672

Stem cells; Progenitor cells; Precursor cells; Oval cells

C12N5/0676

Pancreatic cells

C12N5/0677

Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

C12N5/0678

Stem cells; Progenitor cells; Precursor cells

C12N5/0679

Cells of the gastro-intestinal tract

C12N5/068

Stem cells; Progenitors

C12N5/0681

Cells of the genital tract; Non-germinal cells from gonads

C12N5/0682

Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells oocytes C12N5/0609

C12N5/0683

Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells spermatogonia C12N5/061

C12N5/0684

Cells of the urinary tract or kidneys

C12N5/0685

Bladder epithelial cells

C12N5/0686

Kidney cells

C12N5/0687

Renal stem cells; Renal progenitors

C12N5/0688

Cells from the lungs or the respiratory tract

C12N5/0689

Stem cells; Progenitors

C12N5/069

Vascular Endothelial cells

C12N5/0691

Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels

C12N5/0692

Stem cells; Progenitor cells; Precursor cells

C12N5/0693

Tumour cells; Cancer cells

C12N5/0694

Cells of blood, e.g. leukemia cells, myeloma cells

C12N5/0695

Stem cells; Progenitor cells; Precursor cells

C12N5/0696

Artificially induced pluripotent stem cells, e.g. iPS

C12N5/0697

Artificial constructs associating cells of different lineages, e.g. tissue equivalents blood vessels C12N5/0691

C12N5/0698

Skin equivalents

C12N5/10

Cells modified by introduction of foreign genetic material

C12N5/12

Fused cells, e.g. hybridomas

C12N5/14

Plant cells

C12N5/16

Animal cells

C12N5/163

one of the fusion partners being a B or a T lymphocyte

C12N5/166

resulting from interspecies fusion

C12N7/00

Viruses

Bacteriophages

Compositions thereof

Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

From 2012-03-15 groups C12N7/02 - C12N7/08 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N2710/00-C12N2795/00.

C12N7/02

Recovery or purification

C12N7/025

Packaging cell lines, e.g. transcomplementing cell lines, for production of virus

C12N7/04

Inactivation or attenuation

Producing viral sub-units

C12N7/045

Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered

C12N7/06

Inactivation or attenuation

by chemical treatment

C12N7/08

Inactivation or attenuation

by serial passage of virus

C12N9/00

Enzymes

Proenzymes

Compositions thereof preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D;

enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113

Processes for preparing, activating, inhibiting, separating or purifying enzymes preparation of malt C12C1/00

Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

C12N9/0002

Antibodies with enzymatic activity, e.g. abzymes

C12N9/0004

Oxidoreductases (1.)

C12N9/0006

acting on CH-OH groups as donors (1.1)

C12N9/0008

acting on the aldehyde or oxo group of donors (1.2)

C12N9/001

acting on the CH-CH group of donors (1.3)

C12N9/0012

acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)

C12N9/0014

acting on the CH-NH₂ group of donors (1.4)

C12N9/0016

with NAD or NADP as acceptor (1.4.1)

C12N9/0018

Phenylalanine dehydrogenase (1.4.1.20)

C12N9/002

with a cytochrome as acceptor (1.4.2)

C12N9/0022

with oxygen as acceptor (1.4.3)

C12N9/0024

D-Amino acid oxidase (1.4.3.3)

C12N9/0026

acting on CH-NH groups of donors (1.5)

C12N9/0028

with NAD or NADP as acceptor (1.5.1)

C12N9/003

Dihydrofolate reductase [DHFR] (1.5.1.3)

C12N9/0032

with oxygen as acceptor (1.5.3)

C12N9/0034

Sarcosine oxidase (1.5.3.1)

C12N9/0036

acting on NADH or NADPH (1.6)

C12N9/0038

with a heme protein as acceptor (1.6.2)

C12N9/004

Cytochrome-b5 reductase (1.6.2.2)

C12N9/0042

NADPH-cytochrome P450 reductase (1.6.2.4)

C12N9/0044

acting on other nitrogen compounds as donors (1.7)

C12N9/0046

with oxygen as acceptor (1.7.3)

C12N9/0048

Uricase (1.7.3.3)

C12N9/0051

acting on a sulfur group of donors (1.8)

C12N9/0053

acting on a heme group of donors (1.9)

C12N9/0055

acting on diphenols and related substances as donors (1.10)

C12N9/0057

with oxygen as acceptor (1.10.3)

C12N9/0059

Catechol oxidase (1.10.3.1), i.e. tyrosinase

C12N9/0061

Laccase (1.10.3.2)

C12N9/0063

Ascorbate oxidase (1.10.3.3)

C12N9/0065

acting on hydrogen peroxide as acceptor (1.11)

C12N9/0067

acting on hydrogen as donor (1.12)

C12N9/0069

acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

C12N9/0071

acting on paired donors with incorporation of molecular oxygen (1.14)

C12N9/0073

with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

C12N9/0075

Nitric-oxide synthase (1.14.13.39)

C12N9/0077

with a reduced iron-sulfur protein as one donor (1.14.15)

C12N9/0079

Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)

C12N9/0081

Cholesterol monooxygenase (cytochrome P 450scc)(1.14.15.6)

C12N9/0083

Miscellaneous (1.14.99)

C12N9/0085

Steroid 17 alpha-monooxygenase (1.14.99.9)

C12N9/0087

Steroid 21-monooxygenase (1.14.99.10)

C12N9/0089

acting on superoxide as acceptor (1.15)

C12N9/0091

oxidizing metal ions (1.16)

C12N9/0093

acting on CH or CH₂ groups (1.17)

C12N9/0095

acting on iron-sulfur proteins as donor (1.18)

C12N9/0097

acting on reduced flavodoxin as donor (1.19)

C12N9/10

Transferases (2.) ribonucleases C12N9/22

C12N9/1003

transferring one-carbon groups (2.1)

C12N9/1007

Methyltransferases (general) (2.1.1.)

C12N9/1011

Catechol O-methyltransferase (2.1.1.6)

C12N9/1014

Hydroxymethyl-, formyl-transferases (2.1.2)

C12N9/1018

Carboxy- and carbamoyl transferases (2.1.3)

C12N9/1022

transferring aldehyde or ketonic groups (2.2)

C12N9/1025

Acyltransferases (2.3)

C12N9/1029

transferring groups other than amino-acyl groups (2.3.1)

C12N9/1033

Chloramphenicol O-acetyltransferase (2.3.1.28)

C12N9/1037

Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase

C12N9/104

Aminoacyltransferases (2.3.2)

C12N9/1044

Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII

C12N9/1048

Glycosyltransferases (2.4)

C12N9/1051

Hexosyltransferases (2.4.1)

C12N9/1055

Levansucrase (2.4.1.10)

C12N9/1059

Cellulose synthases (2.4.1.12; 2.4.1.29)

C12N9/1062

Sucrose synthase (2.4.1.13)

C12N9/1066

Sucrose phosphate synthase (2.4.1.14)

C12N9/107

1,4-Alpha-glucan branching enzyme (2.4.1.18)

C12N9/1074

Cyclomaltodextrin glucanotransferase (2.4.1.19)

C12N9/1077

Pentosyltransferases (2.4.2)

C12N9/1081

transferring other glycosyl groups (2.4.99)

C12N9/1085

transferring alkyl or aryl groups other than methyl groups (2.5)

C12N9/1088

Glutathione transferase (2.5.1.18)

C12N9/1092

3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase

C12N9/1096

transferring nitrogenous groups (2.6)

C12N9/12

transferring phosphorus containing groups, e.g. kinases (2.7)

C12N9/1205

Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

C12N9/1211

Thymidine kinase (2.7.1.21)

C12N9/1217

Phosphotransferases with a carboxyl group as acceptor (2.7.2)

C12N9/1223

Phosphotransferases with a nitrogenous group as acceptor (2.7.3)

C12N9/1229

Phosphotransferases with a phosphate group as acceptor (2.7.4)

C12N9/1235

Diphosphotransferases (2.7.6)

C12N9/1241

Nucleotidyltransferases (2.7.7)

C12N9/1247

DNA-directed RNA polymerase (2.7.7.6)

C12N9/1252

DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

C12N9/1258

Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase

C12N9/1264

DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase

C12N9/127

RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

C12N9/1276

RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase

C12N9/1282

RNA uridylyltransferase (2.7.7.52)

C12N9/1288

Transferases for other substituted phosphate groups (2.7.8)

C12N9/1294

Phosphotransferases with paired acceptors (2.7.9)

C12N9/13

transferring sulfur containing groups (2.8)

C12N9/14

Hydrolases (3)

C12N9/16

acting on ester bonds (3.1)

C12N9/18

Carboxylic ester hydrolases

(3.1.1)

C12N9/20

Triglyceride splitting, e.g. by means of lipase

C12N9/22

Ribonucleases

RNAses, DNAses catalytic nucleic acids C12N15/113

C12N9/24

acting on glycosyl compounds (3.2)

C12N9/2402

hydrolysing O- and S- glycosyl compounds (3.2.1)

C12N9/2405

Glucanases

C12N9/2408

acting on alpha -1,4-glucosidic bonds

C12N9/2411

Amylases

C12N9/2414

Alpha-amylase (3.2.1.1.)

C12N9/2417

from microbiological source

C12N9/242

Fungal source

C12N9/2422

from plant source

C12N9/2425

Beta-amylase (3.2.1.2)

C12N9/2428

Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase

C12N9/2431

Beta-fructofuranosidase (3.2.1.26), i.e. invertase

C12N9/2434

acting on beta-1,4-glucosidic bonds

C12N9/2437

Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)

C12N9/244

Endo-1,3(4)-beta-glucanase (3.2.1.6)

C12N9/2442

Chitinase (3.2.1.14)

C12N9/2445

Beta-glucosidase (3.2.1.21)

C12N9/2448

Licheninase (3.2.1.73)

C12N9/2451

acting on alpha-1,6-glucosidic bonds

C12N9/2454

Dextranase (3.2.1.11)

C12N9/2457

Pullulanase (3.2.1.41)

C12N9/246

Isoamylase (3.2.1.68)

C12N9/2462

Lysozyme (3.2.1.17)

C12N9/2465

acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)

C12N9/2468

acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)

C12N9/2471

Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase

C12N9/2474

Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

C12N9/2477

Hemicellulases not provided in a preceding group

C12N9/248

Xylanases

C12N9/2482

Endo-1,4-beta-xylanase (3.2.1.8)

C12N9/2485

Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase

C12N9/2488

Mannanases

C12N9/2491

Beta-mannosidase (3.2.1.25), i.e. mannanase

C12N9/2494

Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase

C12N9/2497

hydrolysing N- glycosyl compounds (3.2.2)

C12N9/48

acting on peptide bonds (3.4)

C12N9/485

Exopeptidases (3.4.11-3.4.19)

C12N9/50

Proteinases

, e.g. Endopeptidases (3.4.21-3.4.25)

C12N9/503

derived from viruses

C12N9/506

derived from RNA viruses

C12N9/52

derived from bacteria

or Archaea

In this group, Archaea, formerly known as Archaebacteria, are classified with bacteria.

C12N9/54

bacteria being Bacillus

C12N9/58

derived from fungi

C12N9/60

from yeast

C12N9/62

from Aspergillus

C12N9/63

derived from plants

C12N9/64

derived from animal tissue

C12N9/6402

from non-mammals

C12N9/6405

not being snakes

C12N9/6408

Serine endopeptidases (3.4.21)

C12N9/641

Cysteine endopeptidases (3.4.22)

C12N9/6413

Aspartic endopeptidases (3.4.23)

C12N9/6416

Metalloendopeptidases (3.4.24)

C12N9/6418

from snakes

C12N9/6421

from mammals

C12N9/6424

Serine endopeptidases (3.4.21)

C12N9/6427

Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)

C12N9/6429

Thrombin (3.4.21.5)

C12N9/6432

Coagulation factor Xa (3.4.21.6)

C12N9/6435

Plasmin (3.4.21.7), i.e. fibrinolysin

C12N9/6437

Coagulation factor VIIa (3.4.21.21)

C12N9/644

Coagulation factor IXa (3.4.21.22)

C12N9/6443

Coagulation factor XIa (3.4.21.27)

C12N9/6445

Kallikreins (3.4.21.34; 3.4.21.35)

C12N9/6448

Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)

C12N9/6451

Coagulation factor XIIa (3.4.21.38)

C12N9/6454

Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases

C12N9/6456

Plasminogen activators

C12N9/6459

t-plasminogen activator (3.4.21.68), i.e. tPA

C12N9/6462

u-Plasminogen activator (3.4.21.73), i.e. urokinase

C12N9/6464

Protein C (3.4.21.69)

C12N9/6467

Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)

C12N9/647

Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups

C12N9/6472

Cysteine endopeptidases (3.4.22)

C12N9/6475

Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)

C12N9/6478

Aspartic endopeptidases (3.4.23)

C12N9/6481

Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)

C12N9/6483

Chymosin (3.4.23.4), i.e. rennin

C12N9/6486

Renin (3.4.23.15)

C12N9/6489

Metalloendopeptidases (3.4.24)

C12N9/6491

Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)

C12N9/6494

Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11

C12N9/6497

Endothelin-converting enzyme (3.4.24.71)

C12N9/78

acting on carbon to nitrogen bonds other than peptide bonds (3.5)

C12N9/80

acting on amide bonds in linear amides

(3.5.1)

C12N9/82

Asparaginase

(3.5.1.1)

C12N9/84

Penicillin amidase

(3.5.1.11)

C12N9/86

acting on amide bonds in cyclic amides, e.g. penicillinase

(3.5.2)

C12N9/88

Lyases (4.)

C12N9/90

Isomerases (5.)

C12N9/92

Glucose isomerase

(5.3.1.5; 5.3.1.9; 5.3.1.18)

C12N9/93

Ligases (6)

C12N9/94

Pancreatin

C12N9/96

Stabilising an enzyme by forming an adduct or a composition

Forming enzyme conjugates

C12N9/98

Preparation of granular or free-flowing enzyme compositions C12N9/96 takes precedence

C12N9/99

Enzyme inactivation by chemical treatment

C12N11/00

Carrier-bound or immobilised enzymes

Carrier-bound or immobilised microbial cells

Preparation thereof

C12N11/02

Enzymes or microbial cells immobilised on or in an organic carrier

C12N11/04

entrapped within the carrier, e.g. gel or hollow fibres

C12N11/06

attached to the carrier via a bridging agent

C12N11/08

the carrier being a synthetic polymer

C12N11/082

obtained by reactions only involving carbon-to-carbon unsaturated bonds

C12N11/084

Polymers containing vinyl alcohol units

C12N11/087

Acrylic polymers

C12N11/089

obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

C12N11/091

Phenol resins

Amino resins

C12N11/093

Polyurethanes

C12N11/096

Polyesters

Polyamides

C12N11/098

formed in the presence of the enzymes or microbial cells

C12N11/10

the carrier being a carbohydrate

C12N11/12

Cellulose or derivatives thereof

C12N11/14

Enzymes or microbial cells immobilised on or in an inorganic carrier

C12N11/16

Enzymes or microbial cells immobilised on or in a biological cell

C12N11/18

Multi-enzyme systems

C12N13/00

Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

C12N15/00

Mutation or genetic engineering

DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification

Use of hosts therefor mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00

C12N15/01

Preparation of mutants without inserting foreign genetic material therein

Screening processes therefor

C12N15/02

Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion

monoclonal antibodies C07K16/00; apparatus for cell fusion C12M

C12N15/03

Bacteria

C12N15/04

Fungi

C12N15/09

Recombinant DNA-technology

C12N15/10

Processes for the isolation, preparation or purification of DNA or RNA chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34

In groups C12N15/10 - C12N15/1096, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N.

C12N15/1003

Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor

C12N15/1006

by means of a solid support carrier, e.g. particles, polymers

C12N15/101

by chromatography, e.g. electrophoresis, ion-exchange, reverse phase

C12N15/1013

by using magnetic beads

C12N15/1017

by filtration, e.g. using filters, frits, membranes

C12N15/102

Mutagenizing nucleic acids

C12N15/1024

In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair

C12N15/1027

by DNA shuffling, e.g. RSR, STEP, RPR

C12N15/1031

mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR

C12N15/1034

Isolating an individual clone by screening libraries

C12N15/1037

Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

C12N15/1041

Ribosome/Polysome display, e.g. SPERT, ARM

C12N15/1044

Preparation or screening of libraries displayed on scaffold proteins

C12N15/1048

SELEX

C12N15/1051

Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors

C12N15/1055

Protein x Protein interaction, e.g. two hybrid selection

C12N15/1058

Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms

C12N15/1062

mRNA-Display, e.g. polypeptide and encoding template are connected covalently

C12N15/1065

Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags

C12N15/1068

Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis

C12N15/1072

Differential gene expression library synthesis, e.g. subtracted libraries, differential screening

C12N15/1075

by coupling phenotype to genotype, not provided for in other groups of this subclass

C12N15/1079

Screening libraries by altering the phenotype or phenotypic trait of the host reporter assays C12N15/1086

C12N15/1082

Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors

C12N15/1086

Preparation or screening of expression libraries, e.g. reporter assays

C12N15/1089

Design, preparation, screening or analysis of libraries using computer algorithms

C12N15/1093

General methods of preparing gene libraries, not provided for in other subgroups

C12N15/1096

cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR

C12N15/11

DNA or RNA fragments

Modified forms thereof DNA or RNA not used in recombinant technology, C07H21/00

Non-coding nucleic acids having a biological activity

Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N9/00 according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups C12N15/11 - C12N15/117 cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The C12N2303/00 ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group C12N15/111

C12N15/111

General methods applicable to biologically active non-coding nucleic acids

C12N15/113

Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218

C12N15/1131

against viruses

C12N15/1132

against retroviridae, e.g. HIV

C12N15/1133

against herpetoviridae, e.g. HSV

C12N15/1135

against oncogenes or tumor suppressor genes

C12N15/1136

against growth factors, growth regulators, cytokines, lymphokines or hormones

C12N15/1137

against enzymes viral enzymes C12N15/1131; receptors C12N15/1138

C12N15/1138

against receptors or cell surface proteins

C12N15/115

Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

; Nucleic acids binding to non-nucleic acids, e.g. aptamers

Aptamers fused to compounds which are already classified in groups C12N15/11 - C12N15/117, are classified with the corresponding compound

C12N15/117

Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

C12N15/52

Genes encoding for enzymes or proenzymes

In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

C12N15/62

DNA sequences coding for fusion proteins

In this group, the following term is used with the meaning indicated:

"fusion" means the fusion of two different proteins.

C12N15/625

containing a sequence coding for a signal sequence

C12N15/63

Introduction of foreign genetic material using vectors

Vectors

Use of hosts therefor

Regulation of expression

C12N15/635

Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline

C12N15/64

General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

In the group C12N15/64, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N

C12N15/65

using markers enzymes used as markers C12N15/52

In the group C12N15/65, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N

C12N15/66

General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation

Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

In this group, the following expression is used with the meaning indicated:

"non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.

In the group C12N15/66, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N

C12N15/67

General methods for enhancing the expression

C12N15/68

Stabilisation of the vector

C12N15/69

Increasing the copy number of the vector

C12N15/70

Vectors or expression systems specially adapted for E. coli

This group covers the use of E. coli as host.

Shuttle vectors also replicating in E. coli are classified according to the other host.

C12N15/71

Expression systems using regulatory sequences derived from the trp-operon

C12N15/72

Expression systems using regulatory sequences derived from the lac-operon

C12N15/73

Expression systems using phage (lambda) regulatory sequences

C12N15/74

Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

This group covers the use of prokaryotes as hosts.

C12N15/743

for Agrobacterium; Rhizobium; Bradyrhizobium

C12N15/746

for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)

C12N15/75

for Bacillus

C12N15/76

for Actinomyces

for Streptomyces

C12N15/77

for Corynebacterium

for Brevibacterium

C12N15/78

for Pseudomonas

C12N15/79

Vectors or expression systems specially adapted for eukaryotic hosts

This group covers the use of eukaryotes as hosts.

C12N15/80

for fungi

C12N15/81

for yeasts

C12N15/815

for yeasts other than Saccharomyces

C12N15/82

for plant cells

, e.g. plant artificial chromosomes (PACs)

Documents are being continuously reclassified into this new classification scheme. See Warning notes below

C12N15/8201

Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation

C12N15/8202

by biological means, e.g. cell mediated or natural vector

C12N15/8203

Virus mediated transformation

C12N15/8205

Agrobacterium mediated transformation

C12N15/8206

by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated

C12N15/8207

by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers

C12N15/8209

Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers

Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N15/8209

C12N15/821

Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers

C12N15/8212

Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid

C12N15/8213

Targeted insertion of genes into the plant genome by homologous recombination

C12N15/8214

Plastid transformation

C12N15/8216

Methods for controlling, regulating or enhancing expression of transgenes in plant cells

C12N15/8217

Gene switch

C12N15/8218

Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]

C12N15/822

Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression

C12N15/8221

Transit peptides

C12N15/8222

Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation

C12N15/8223

Vegetative tissue-specific promoters

C12N15/8225

Leaf-specific, e.g. including petioles, stomata

C12N15/8226

Stem-specific, e.g. including tubers, beets

C12N15/8227

Root-specific

C12N15/8229

Meristem-specific, e.g. nodal, apical

C12N15/823

Reproductive tissue-specific promoters

C12N15/8231

Male-specific, e.g. anther, tapetum, pollen

C12N15/8233

Female-specific, e.g. pistil, ovule

C12N15/8234

Seed-specific, e.g. embryo, endosperm

C12N15/8235

Fruit-specific

C12N15/8237

Externally regulated expression systems

C12N15/8238

chemically inducible, e.g. tetracycline

C12N15/8239

pathogen inducible

C12N15/8241

Phenotypically and genetically modified plants via recombinant DNA technology

C12N15/8242

with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits

C12N15/8243

involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine

C12N15/8245

involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis

C12N15/8246

Non-starch polysaccharides, e.g. cellulose, fructans, levans

C12N15/8247

involving modified lipid metabolism, e.g. seed oil composition

C12N15/8249

involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life

C12N15/825

involving pigment biosynthesis

Transgenic plants with altered flower morphology are also classified in this group

C12N15/8251

Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis

C12N15/8253

Methionine or cysteine

C12N15/8254

Tryptophan or lysine

C12N15/8255

involving lignin biosynthesis

C12N15/8257

for the production of primary gene products, e.g. pharmaceutical products, interferon

C12N15/8258

for the production of oral vaccines (antigens) or immunoglobulins

C12N15/8259

Phytoremediation

C12N15/8261

with agronomic (input) traits, e.g. crop yield

C12N15/8262

involving plant development

C12N15/8263

Ablation; Apoptosis

C12N15/8265

Transgene containment, e.g. gene dispersal

C12N15/8266

Abscission; Dehiscence; Senescence

C12N15/8267

Seed dormancy, germination or sprouting

C12N15/8269

Photosynthesis

C12N15/827

Flower development or morphology, e.g. flowering promoting factor [FPF]

C12N15/8271

for stress resistance, e.g. heavy metal resistance

C12N15/8273

for drought, cold, salt resistance

C12N15/8274

for herbicide resistance

C12N15/8275

Glyphosate

C12N15/8277

Phosphinotricin

C12N15/8278

Sulfonylurea

C12N15/8279

for biotic stress resistance, pathogen resistance, disease resistance

C12N15/8281

for bacterial resistance

C12N15/8282

for fungal resistance

C12N15/8283

for virus resistance

C12N15/8285

for nematode resistance

C12N15/8286

for insect resistance

C12N15/8287

for fertility modification, e.g. apomixis

C12N15/8289

Male sterility

C12N15/829

Female sterility

C12N15/8291

Hormone-influenced development

C12N15/8293

Abscisic acid [ABA]

C12N15/8294

Auxins

C12N15/8295

Cytokinins

C12N15/8297

Gibberellins; GA3

C12N15/8298

Brassinosteroids

C12N15/85

for animal cells

C12N15/8509

for producing genetically modified animals, e.g. transgenic

Additional aspects of the modified animals are classified in the groups A01K2207/00 - A01K2267/00

C12N2015/8518

expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

C12N2015/8527

for producing animal models, e.g. for tests or diseases

C12N2015/8536

Animal models for genetic diseases

C12N2015/8545

for Alzheimer''s disease

C12N2015/8554

Invertebrates models for Alzheimer''s disease

C12N2015/8563

for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus

C12N2015/8572

Animal models for proliferative diseases, e.g. comprising an oncogene

C12N2015/8581

Animal models for infectious diseases, e.g. AIDS

C12N2015/859

Animal models comprising reporter system for screening tests

C12N15/86

Viral vectors

From 2012-03-15 groups C12N15/861 - C12N15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N2710/00-C12N2795/00

C12N15/861

Adenoviral vectors

C12N15/8613

Chimaeric vector systems comprising heterologous sequences for production of another viral vector

C12N15/8616

Special methods for targeting systems

C12N15/863

Poxviral vectors,

e.g. entomopoxvirus

C12N15/8633

Avian poxviral vectors

C12N15/8636

Vaccina virus vectors

C12N15/864

Parvoviral vectors

, e.g. parvovirus, densovirus

C12N15/8645

Adeno-associated virus

C12N15/866

Baculoviral vectors

C12N15/867

Retroviral vectors

C12N15/8673

Special methods for packaging systems

C12N15/8676

Special methods for targeting systems

C12N15/869

Herpesviral vectors

C12N15/8695

Herpes simplex virus-based vectors

C12N15/87

Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

C12N15/873

Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos

C12N15/877

Techniques for producing new mammalian cloned embryos

C12N15/8771

Bovine embryos

C12N15/8772

Caprine embryos

C12N15/8773

Ovine embryos

C12N15/8775

Murine embryos

C12N15/8776

Primate embryos

C12N15/8777

Rabbit embryos

C12N15/8778

Swine embryos

C12N15/88

using microencapsulation, e.g. using

amphiphile

liposome vesicle

C12N15/89

using microinjection

C12N15/895

using biolistic methods

C12N15/90

Stable introduction of foreign DNA into chromosome

C12N15/902

using homologous recombination

C12N15/905

in yeast

C12N15/907

in mammalian cells

C12N2303/00

Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids

Indexing codes of group C12N2303/00 are only used in combination with group C12N15/111

C12N2310/00

Structure or type of the nucleic acid

In groups C12N2310/00 - C12N2310/533, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N.

C12N2310/10

Type of nucleic acid

C12N2310/11

Antisense

C12N2310/111

spanning the whole gene, or a large part of it

C12N2310/113

targeting other non-coding nucleic acids, e.g. antagomirs

C12N2310/12

catalytic nucleic acids, e.g. ribozymes

C12N2310/121

Hammerhead

C12N2310/122

Hairpin

C12N2310/123

Hepatitis delta

C12N2310/124

based on group I or II introns

C12N2310/1241

Tetrahymena

C12N2310/126

involving RNAse P

C12N2310/127

DNAzymes

C12N2310/128

processing or releasing ribozyme

C12N2310/13

Decoys

C12N2310/14

interfering N.A.

C12N2310/141

MicroRNAs, miRNAs

C12N2310/15

Nucleic acids forming more than 2 strands, e.g. TFOs

C12N2310/151

more than 3 strands, e.g. tetrads, H-DNA

C12N2310/152

on a single-stranded target, e.g. fold-back TFOs

C12N2310/153

with the aid of a protein, e.g. recombinase

C12N2310/16

Aptamers

C12N2310/17

Immunomodulatory nucleic acids

C12N2310/18

acting by a non-sequence specific mechanism other than C12N2310/16 or C12N2310/17

C12N2310/20

involving clustered regularly interspaced short palindromic repeats [CRISPRs]

C12N2310/30

Chemical structure

C12N2310/31

of the backbone

C12N2310/311

Phosphotriesters

C12N2310/312

Phosphonates

C12N2310/3125

Methylphosphonates

C12N2310/313

Phosphorodithioates

C12N2310/314

Phosphoramidates

C12N2310/3145

with the nitrogen in 3' or 5'-position

C12N2310/315

Phosphorothioates

C12N2310/316

Phosphonothioates

C12N2310/317

with an inverted bond, e.g. a cap structure

C12N2310/318

where the PO2 is completely replaced, e.g. MMI or formacetal

C12N2310/3181

Peptide nucleic acid, PNA

C12N2310/3183

Diol linkers, e.g. glycols or propanediols

C12N2310/319

linked by 2'-5' linkages, i.e. having a free 3'-position

C12N2310/32

of the sugar

C12N2310/321

2'-O-R Modification

C12N2310/322

2'-R Modification

C12N2310/323

modified ring structure

C12N2310/3231

having an additional ring, e.g. LNA, ENA

C12N2310/3233

Morpholino-type ring

C12N2310/3235

having the O of the ribose replaced by another atom

C12N2310/33

of the base

C12N2310/331

Universal or degenerate base

C12N2310/332

Abasic residue

C12N2310/333

Modified A

C12N2310/334

Modified C

C12N2310/3341

5-Methylcytosine

C12N2310/335

Modified T or U

C12N2310/336

Modified G

C12N2310/337

in alpha-anomeric form

C12N2310/34

Spatial arrangement of the modifications

C12N2310/341

Gapmers, i.e. of the type ===---===

C12N2310/342

Hemimers, i.e. of the type ====----

C12N2310/343

having patterns, e.g. ==--==--==--

C12N2310/344

Position-specific modifications, e.g. on every purine, at the 3'-end

C12N2310/345

having at least two different backbone modifications

C12N2310/346

having a combination of backbone and sugar modifications

C12N2310/35

Nature of the modification

C12N2310/351

Conjugate

C12N2310/3511

intercalating or cleaving agent

C12N2310/3513

Protein

Peptide

C12N2310/3515

Lipophilic moiety, e.g. cholesterol

C12N2310/3517

Marker

Tag

C12N2310/3519

Fusion with another nucleic acid

C12N2310/352

linked to the nucleic acid via a carbon atom

C12N2310/3521

Methyl

C12N2310/3523

Allyl

C12N2310/3525

MOE, methoxyethoxy

C12N2310/3527

Other alkyl chain

C12N2310/3529

Aromatic substituent

C12N2310/353

linked to the nucleic acid via an atom other than carbon

C12N2310/3531

Hydrogen

C12N2310/3533

Halogen

C12N2310/3535

Nitrogen

C12N2310/50

Physical structure

C12N2310/51

in polymeric form, e.g. multimers, concatemers

C12N2310/52

branched

C12N2310/53

partially self-complementary or closed

C12N2310/531

Stem-loop

Hairpin

C12N2310/532

Closed or circular

C12N2310/533

having a mismatch or nick in at least one of the strands

C12N2320/00

Applications

Uses

C12N2320/10

in screening processes

C12N2320/11

for the determination of target sites, i.e. of active nucleic acids

C12N2320/12

in functional genomics, i.e. for the determination of gene function

C12N2320/13

in a process of directed evolution, e.g. SELEX, acquiring a new function

C12N2320/30

Special therapeutic applications

C12N2320/31

Combination therapy

C12N2320/32

Special delivery means, e.g. tissue-specific

C12N2320/33

Alteration of splicing

C12N2320/34

Allele or polymorphism specific uses

C12N2320/35

based on a specific dosage / administration regimen

C12N2320/50

Methods for regulating/modulating their activity

C12N2320/51

modulating the chemical stability, e.g. nuclease-resistance

C12N2320/52

modulating the physical stability, e.g. GC-content

C12N2320/53

reducing unwanted side-effects

C12N2330/00

Production

C12N2330/10

naturally occurring

C12N2330/30

chemically synthesised

C12N2330/31

Libraries, arrays

C12N2330/50

Biochemical production, i.e. in a transformed host cell

C12N2330/51

Specially adapted vectors

C12N2500/00

Specific components of cell culture medium

C12N2500/02

Atmosphere, e.g. low oxygen conditions

C12N2500/05

Inorganic components

C12N2500/10

Metals

Metal chelators cobalamine C12N2500/38

C12N2500/12

Light metals, i.e. alkali, alkaline earth, Be, Al, Mg

C12N2500/14

Calcium

Ca chelators

Calcitonin

C12N2500/16

Magnesium

Mg chelators

C12N2500/20

Transition metals

C12N2500/22

Zinc

Zn chelators insulin-zinc complexes C12N2501/33

C12N2500/24

Iron

Fe chelators

Transferrin

C12N2500/25

Insulin-transferrin

Insulin-transferrin-selenium

C12N2500/30

Organic components metal chelators C12N2500/10; calcitonin C12N2500/14; transferrin C12N2500/24

C12N2500/32

Amino acids

C12N2500/33

other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine

C12N2500/34

Sugars

C12N2500/35

Polyols, e.g. glycerin, inositol

C12N2500/36

Lipids

C12N2500/38

Vitamins

C12N2500/40

Nucleotides, nucleosides, bases cyclic nucleotides C12N2501/01, anti-neoplasic drugs C12N2501/06

C12N2500/42

Organic phosphate, e.g. beta glycerophosphate

C12N2500/44

Thiols, e.g. mercaptoethanol

C12N2500/46

Amines, e.g. putrescine

C12N2500/50

Soluble polymers, e.g. polyethyleneglycol [PEG]

C12N2500/60

Buffer, e.g. pH regulation, osmotic pressure

C12N2500/62

DMSO

C12N2500/70

Undefined extracts conditioned medium C12N2502/00

C12N2500/72

from bacteria

C12N2500/74

from fungi, e.g. yeasts

C12N2500/76

from plants

C12N2500/78

from protozoa

C12N2500/80

from animals

C12N2500/82

from invertebrates

C12N2500/84

from mammals

C12N2500/90

Serum-free medium, which may still contain naturally-sourced components

C12N2500/92

Medium free of human- or animal-derived components

C12N2500/95

Protein-free medium and culture conditions

C12N2500/98

Xeno-free medium and culture conditions

C12N2500/99

Serum-free medium

This group is no longer used for the classification of new documents as from 2012-01-01. The backlog of this group is being continuously reclassified to C12N2500/90 - C12N2500/98

C12N2501/00

Active agents used in cell culture processes, e.g. differentation

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in C07K14/00, but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

C12N2501/01

Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin

C12N2501/02

Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

C12N2501/03

Compounds acting on the NO pathway, e.g. nitrososarginine

C12N2501/04

Immunosuppressors, e.g. cyclosporin, tacrolimus

C12N2501/05

Adjuvants

C12N2501/051

Lipid A (MPA, MPL)

C12N2501/052

Lipopolysaccharides [LPS]

C12N2501/054

Muramyle peptides

C12N2501/056

Immunostimulating oligonucleotides, e.g. CpG

C12N2501/06

Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide

C12N2501/065

Modulators of histone acetylation

C12N2501/07

Heat shock proteins

C12N2501/10

Growth factors

C12N2501/105

Insulin-like growth factors [IGF]

C12N2501/11

Epidermal growth factor [EGF]

C12N2501/113

Acidic fibroblast growth factor (aFGF, FGF-1)

C12N2501/115

Basic fibroblast growth factor (bFGF, FGF-2)

C12N2501/117

Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)

C12N2501/119

Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10

C12N2501/12

Hepatocyte growth factor [HGF]

C12N2501/125

Stem cell factor [SCF], c-kit ligand [KL]

C12N2501/13

Nerve growth factor [NGF]

Brain-derived neurotrophic factor [BDNF]

Cilliary neurotrophic factor [CNTF]

Glial-derived neurotrophic factor [GDNF]

Neurotrophins [NT]

Neuregulins

C12N2501/135

Platelet-derived growth factor [PDGF]

C12N2501/14

Erythropoietin [EPO]

C12N2501/145

Thrombopoietin [TPO]

C12N2501/148

Transforming growth factor alpha [TGF-a]

C12N2501/15

Transforming growth factor beta (TGF-β)

C12N2501/155

Bone morphogenic proteins [BMP]

Osteogenins

Osteogenic factor

Bone inducing factor

C12N2501/16

Activin

Inhibin

Mullerian inhibiting substance

C12N2501/165

Vascular endothelial growth factor [VEGF]

C12N2501/17

Angiopoietin

C12N2501/175

Cardiotrophin

C12N2501/18

Liver cell growth factor (LCGF, Gly-His-Lys)

C12N2501/185

Osteoprotegerin

Osteoclast differentiation factor (ODF, RANKL)

C12N2501/19

Growth and differentiation factors [GDF]

C12N2501/195

Heregulin, neu differentiation factor

C12N2501/20

Cytokines

Chemokines

C12N2501/21

Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

C12N2501/22

Colony stimulating factors (G-CSF, GM-CSF)

C12N2501/23

Interleukins [IL]

C12N2501/2301

Interleukin-1 (IL-1)

C12N2501/2302

Interleukin-2 (IL-2)

C12N2501/2303

Interleukin-3 (IL-3)

C12N2501/2304

Interleukin-4 (IL-4)

C12N2501/2305

Interleukin-5 (IL-5)

C12N2501/2306

Interleukin-6 (IL-6)

C12N2501/2307

Interleukin-7 (IL-7)

C12N2501/2308

Interleukin-8 (IL-8)

C12N2501/2309

Interleukin-9 (IL-9)

C12N2501/231

Interleukin-10 (IL-10)

C12N2501/2311

Interleukin-11 (IL-11)

C12N2501/2312

Interleukin-12 (IL-12)

C12N2501/2313

Interleukin-13 (IL-13)

C12N2501/2314

Interleukin-14 (IL-14)

C12N2501/2315

Interleukin-15 (IL-15)

C12N2501/2316

Interleukin-16 (IL-16)

C12N2501/2317

Interleukin-17 (IL-17)

C12N2501/2318

Interleukin-18 (IL-18)

C12N2501/2319

Interleukin-19 (IL-19)

C12N2501/232

Interleukin-20 (IL-20)

C12N2501/2321

Interleukin-21 (IL-21)

C12N2501/2322

Interleukin-22 (IL-22)

C12N2501/2323

Interleukin-23 (IL-23)

C12N2501/2324

Interleukin-24 (IL-24)

C12N2501/2325

Interleukin-25 (IL-25)

C12N2501/2326

Interleukin-26 (IL-26)

C12N2501/2327

Interleukin-27 (IL-27)

C12N2501/2328

Interleukin-28 (IL-28)

C12N2501/2329

Interleukin-29 (IL-29)

C12N2501/233

Interleukin-30 (IL-30)

C12N2501/2331

Interleukin-31 (IL-31)

C12N2501/2332

Interleukin-32 (IL-32)

C12N2501/2333

Interleukin-33 (IL-33)

C12N2501/2334

Interleukin-34 (IL-34)

C12N2501/2335

Interleukin-35 (IL-35)

C12N2501/235

Leukemia inhibitory factor [LIF]

C12N2501/237

Oncostatin M [OSM]

C12N2501/24

Interferons [IFN]

C12N2501/25

Tumour necrosing factors [TNF]

C12N2501/26

Flt-3 ligand (CD135L, flk-2 ligand)

C12N2501/30

Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N2501/85

C12N2501/305

Growth hormone [GH], aka. somatotropin

C12N2501/31

Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]

Chorionic gonadotropins

C12N2501/315

Prolactin

C12N2501/32

Angiotensins [AT], angiotensinogen

C12N2501/33

Insulin together with transferrin C12N2500/25; Insulin-like growth factors C12N2501/105

C12N2501/335

Glucagon

Glucagon-like peptide [GLP]

Exendin

C12N2501/34

Calcitonin

Calcitonin-gene related peptide [CGRO]

Amylin

C12N2501/345

Gastrin

Cholecystokinins [CCK]

C12N2501/35

Vasoactive intestinal peptide [VIP]

Pituitary adenylate cyclase activating polypeptide [PACAP]

C12N2501/355

Leptin

C12N2501/36

Somatostatin

C12N2501/365

Endothelin

C12N2501/37

Parathyroid hormone [PTH]

C12N2501/375

Thyroid stimulating hormone [TSH]

C12N2501/38

with nuclear receptors

C12N2501/385

of the family of the retinoic acid recptor, e.g. RAR, RXR

Peroxisome proliferator-activated receptor [PPAR]

C12N2501/39

Steroid hormones

C12N2501/392

Sexual steroids

C12N2501/395

Thyroid hormones

C12N2501/40

Regulators of development

C12N2501/405

Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

C12N2501/41

Hedgehog proteins

Cyclopamine (inhibitor)

C12N2501/415

Wnt

Frizzeled

C12N2501/42

Notch

Delta

Jagged

Serrate

C12N2501/48

Regulators of apoptosis

C12N2501/50

Cell markers

Cell surface determinants

C12N2501/505

CD4

CD8

C12N2501/51

B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)

C12N2501/515

CD3, T-cell receptor complex

C12N2501/52

CD40, CD40-ligand (CD154)

C12N2501/53

CD2

C12N2501/58

Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)

C12N2501/585

Integrins

C12N2501/59

Lectins

C12N2501/599

with CD designations not provided for elsewhere

C12N2501/60

Transcription factors

C12N2501/602

Sox-2

C12N2501/603

Oct-3/4

C12N2501/604

Klf-4

C12N2501/605

Nanog

C12N2501/606

c-Myc

C12N2501/608

Lin28

C12N2501/65

MicroRNA

C12N2501/70

Enzymes

C12N2501/71

Oxidoreductases (EC 1.)

C12N2501/72

Transferases (EC 2.) acetylation of histones C12N2501/065

C12N2501/724

Glycosyltransferases (EC 2.4.)

C12N2501/727

Kinases (EC 2.7.)

C12N2501/73

Hydrolases (EC 3.)

C12N2501/734

Proteases (EC 3.4.)

C12N2501/80

Neurotransmitters

Neurohormones

C12N2501/805

Acetylcholine

C12N2501/81

Adrenaline

C12N2501/815

Dopamine

C12N2501/82

Histamine

C12N2501/825

Serotonine (5-HT)

Melatonine

C12N2501/83

Tachykinins, e.g. substance P

C12N2501/835

Neuropeptide Y [NPY]

Peptide YY [PYY]

C12N2501/84

Excitatory amino acids

C12N2501/845

Gamma amino butyric acid [GABA]

C12N2501/85

Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

C12N2501/855

Corticotropin [ACTH]

C12N2501/86

Melanocyte-stimulating hormone [MSH]

C12N2501/90

Polysaccharides

C12N2501/905

Hyaluronic acid

C12N2501/91

Heparin

C12N2501/998

Proteins not provided for elsewhere

Classification by pathway does not apply.

C12N2501/999

Small molecules not provided for elsewhere

Classification by pathway does not apply.

C12N2502/00

Coculture with

Conditioned medium produced by

C12N2502/02

embryonic cells

C12N2502/025

extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

C12N2502/03

non-embryonic pluripotent stem cells

C12N2502/04

germ cells

C12N2502/07

endocrine cells

C12N2502/072

adrenal cells

C12N2502/074

pinealocytes

C12N2502/076

pituitary cells

C12N2502/078

thyroid, parathyroid cells

C12N2502/08

cells of the nervous system

C12N2502/081

neurons

C12N2502/083

sensory transducers

C12N2502/085

eye cells

C12N2502/086

glial cells

C12N2502/088

neural stem cells

C12N2502/09

epidermal cells, skin cells, oral mucosa cells

C12N2502/091

melanocytes

C12N2502/092

hair cells

C12N2502/094

keratinocytes

C12N2502/095

mammary cells

C12N2502/097

oral mucosa cells

C12N2502/098

cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands

C12N2502/11

blood or immune system cells

C12N2502/1107

B cells

C12N2502/1114

T cells

C12N2502/1121

Dendritic cells

C12N2502/1128

Erythrocytes

C12N2502/1135

Granulocytes

C12N2502/1142

Osteoclasts

C12N2502/115

Platelets, megakaryocytes

C12N2502/1157

Monocytes, macrophages

C12N2502/1164

NK cells

C12N2502/1171

Haematopoietic stem cells

C12N2502/1178

Spleen cells

C12N2502/1185

Thymus cells

C12N2502/1192

Lymphatic cells

C12N2502/13

connective tissue cells

generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

C12N2502/1305

Adipocytes

C12N2502/1311

Osteocytes, osteoblasts, odontoblasts

C12N2502/1317

Chondrocytes

C12N2502/1323

Adult fibroblasts

C12N2502/1329

Cardiomyocytes

C12N2502/1335

Skeletal muscle cells, myocytes, myoblasts, myotubes

C12N2502/1341

Tenocytes, cells from tendons and ligaments

C12N2502/1347

Smooth muscle cells

C12N2502/1352

Mesenchymal stem cells

C12N2502/1358

Bone marrow mesenchymal stem cells (BM-MSC)

C12N2502/1364

Dental pulp stem cells, dental follicle stem cells

C12N2502/137

Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood

C12N2502/1376

Mesenchymal stem cells from hair follicles

C12N2502/1382

Adipose-derived stem cells [ADSC], adipose stromal stem cells

C12N2502/1388

Mesenchymal stem cells from other natural sources

C12N2502/1394

Bone marrow stromal cells

whole marrow

C12N2502/14

hepatocytes

C12N2502/22

pancreatic cells

C12N2502/23

Gastro-intestinal tract cells

C12N2502/24

Genital tract cells, non-germinal cells from gonads

C12N2502/243

Cells of the female genital tract, non-germinal ovarian cells

C12N2502/246

Cells of the male genital tract, non-germinal testis cells

C12N2502/25

Urinary tract cells, renal cells

C12N2502/253

Bladder cells

C12N2502/256

Renal cells

C12N2502/27

Lung cells, respiratory tract cells

C12N2502/28

Vascular endothelial cells

C12N2502/30

tumour cells

C12N2502/45

Artificially induced pluripotent stem cells

C12N2502/50

invertebrate cells

C12N2502/70

Non-animal cells

C12N2502/99

genetically modified cells

Use C12N2501/00 to index the expressed products.

C12N2503/00

Use of cells in diagnostics

C12N2503/02

Drug screening

C12N2503/04

Screening or testing on artificial tissues

C12N2503/06

Screening or testing on artificial skin

C12N2506/00

Differentiation of animal cells from one lineage to another

Differentiation of pluripotent cells

This scheme indexes the starting point of a differentiation process and is used in combination with classification in C12N5/06 for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

C12N2506/02

from embryonic cells

C12N2506/025

from extra-embryonic cells, e.g. trophoblast, placenta

C12N2506/03

from non-embryonic pluripotent stem cells

C12N2506/04

from germ cells

C12N2506/07

from endocrine cells

C12N2506/072

from adrenal cells

C12N2506/074

from pinealocytes

C12N2506/076

from pituitary cells

C12N2506/078

from thyroid, parathyroid cells

C12N2506/08

from cells of the nervous system

C12N2506/09

from epidermal cells, from skin cells, from oral mucosa cells

C12N2506/091

from melanocytes

C12N2506/092

from hair cells

C12N2506/094

from keratinocytes

C12N2506/095

from mammary cells

C12N2506/097

from oral mucosa cells

C12N2506/098

from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands

C12N2506/11

from blood or immune system cells

C12N2506/115

from monocytes, from macrophages

C12N2506/13

from connective tissue cells, from mesenchymal cells

C12N2506/1307

from adult fibroblasts

C12N2506/1315

from cardiomyocytes

C12N2506/1323

from skeletal muscle cells

C12N2506/133

from tenocytes

C12N2506/1338

from smooth muscle cells

C12N2506/1346

from mesenchymal stem cells

C12N2506/1353

from bone marrow mesenchymal stem cells (BM-MSC)

C12N2506/1361

from dental pulp or dental follicle stem cells

C12N2506/1369

from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood

C12N2506/1376

from mesenchymal stem cells derived from hair follicles

C12N2506/1384

from adipose-derived stem cells [ADSC], from adipose stromal stem cells

C12N2506/1392

from mesenchymal stem cells from other natural sources

C12N2506/14

from hepatocytes

C12N2506/22

from pancreatic cells

C12N2506/23

from cells of the gastro-intestinal tract

C12N2506/24

from cells of the genital tract, from non-germinal gonad cells

C12N2506/243

from cells of the female genital tract cells, from non-germinal ovarian cells

C12N2506/246

from cells of the male genital tract cells, from non-germinal testis cells

C12N2506/25

from renal cells, from cells of the urinary tract

C12N2506/27

from lung cells, from cells of the respiratory tract

C12N2506/28

from vascular endothelial cells

C12N2506/30

from cancer cells, e.g. reversion of tumour cells

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under C12N5/0693.

C12N2506/45

from artificially induced pluripotent stem cells

C12N2509/00

Methods for the dissociation of cells, e.g. specific use of enzymes

C12N2509/10

Mechanical dissociation

C12N2510/00

Genetically modified cells

C12N2510/02

Cells for production

C12N2510/04

Immortalised cells

C12N2511/00

Cells for large scale production

C12N2513/00

3D culture

C12N2517/00

Cells related to new breeds of animals

C12N2517/02

Cells from transgenic animals

C12N2517/04

Cells produced using nuclear transfer

C12N2517/10

Conditioning of cells for in vitro fecondation or nuclear transfer

C12N2521/00

Culture process characterised by the use of hydrostatic pressure, flow or shear forces

C12N2521/10

Sound, e.g. ultrasounds

C12N2523/00

Culture process characterised by temperature

C12N2525/00

Culture process characterised by gravity, e.g. microgravity

C12N2527/00

Culture process characterised by the use of mechanical forces, e.g. strain, vibration

C12N2529/00

Culture process characterised by the use of electromagnetic stimulation

C12N2529/10

Stimulation by light

C12N2531/00

Microcarriers

C12N2533/00

Supports or coatings for cell culture, characterised by material

C12N2533/10

Mineral substrates

C12N2533/12

Glass

C12N2533/14

Ceramic

C12N2533/18

Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells

C12N2533/20

Small organic molecules

C12N2533/30

Synthetic polymers thermoreactive polymers, e.g. PNIPAm, C12N2539/10

C12N2533/32

Polylysine, polyornithine

C12N2533/40

Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA)

Bioresorbable polymers

C12N2533/50

Proteins

C12N2533/52

Fibronectin

Laminin

C12N2533/54

Collagen

Gelatin

C12N2533/56

Fibrin

Thrombin

C12N2533/70

Polysaccharides

C12N2533/72

Chitin, chitosan

C12N2533/74

Alginate

C12N2533/76

Agarose, agar-agar

C12N2533/78

Cellulose

C12N2533/80

Hyaluronan

C12N2533/90

Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

C12N2533/92

Amnion

Decellularised dermis or mucosa

C12N2535/00

Supports or coatings for cell culture characterised by topography

C12N2535/10

Patterned coating

C12N2537/00

Supports and/or coatings for cell culture characterised by physical or chemical treatment

C12N2537/10

Cross-linking

C12N2539/00

Supports and/or coatings for cell culture characterised by properties

C12N2539/10

Coating allowing for selective detachment of cells, e.g. thermoreactive coating

C12N2710/00

Viruses

C12N2710/00

dsDNA viruses

C12N2710/00011

Details

C12N2710/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/00023

Virus like particles [VLP]

C12N2710/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/00041

Use of virus, viral particle or viral elements as a vector

C12N2710/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/00043

viral genome or elements thereof as genetic vector

C12N2710/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/00045

Special targeting system for viral vectors

C12N2710/00051

Methods of production or purification of viral material

C12N2710/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/00061

Methods of inactivation or attenuation

C12N2710/00062

by genetic engineering

C12N2710/00063

by chemical treatment

C12N2710/00064

by serial passage

C12N2710/00071

Demonstrated in vivo effect

C12N2710/00088

for redistribution

C12N2710/10011

Adenoviridae

C12N2710/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/10023

Virus like particles [VLP]

C12N2710/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/10041

Use of virus, viral particle or viral elements as a vector

C12N2710/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/10043

viral genome or elements thereof as genetic vector

C12N2710/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/10045

Special targeting system for viral vectors

C12N2710/10051

Methods of production or purification of viral material

C12N2710/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/10061

Methods of inactivation or attenuation

C12N2710/10062

by genetic engineering

C12N2710/10063

by chemical treatment

C12N2710/10064

by serial passage

C12N2710/10071

Demonstrated in vivo effect

C12N2710/10088

for redistribution

C12N2710/10111

Atadenovirus, e.g. ovine adenovirus D

C12N2710/10121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/10122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/10123

Virus like particles [VLP]

C12N2710/10131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/10132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/10133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/10134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/10141

Use of virus, viral particle or viral elements as a vector

C12N2710/10142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/10143

viral genome or elements thereof as genetic vector

C12N2710/10144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/10145

Special targeting system for viral vectors

C12N2710/10151

Methods of production or purification of viral material

C12N2710/10152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/10161

Methods of inactivation or attenuation

C12N2710/10162

by genetic engineering

C12N2710/10163

by chemical treatment

C12N2710/10164

by serial passage

C12N2710/10171

Demonstrated in vivo effect

C12N2710/10188

for redistribution

C12N2710/10211

Aviadenovirus, e.g. fowl adenovirus A

C12N2710/10221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/10222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/10223

Virus like particles [VLP]

C12N2710/10231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/10232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/10233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/10234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/10241

Use of virus, viral particle or viral elements as a vector

C12N2710/10242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/10243

viral genome or elements thereof as genetic vector

C12N2710/10244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/10245

Special targeting system for viral vectors

C12N2710/10251

Methods of production or purification of viral material

C12N2710/10252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/10261

Methods of inactivation or attenuation

C12N2710/10262

by genetic engineering

C12N2710/10263

by chemical treatment

C12N2710/10264

by serial passage

C12N2710/10271

Demonstrated in vivo effect

C12N2710/10288

for redistribution

C12N2710/10311

Mastadenovirus, e.g. human or simian adenoviruses

C12N2710/10321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/10322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/10323

Virus like particles [VLP]

C12N2710/10331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/10332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/10333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/10334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/10341

Use of virus, viral particle or viral elements as a vector

C12N2710/10342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/10343

viral genome or elements thereof as genetic vector

C12N2710/10344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/10345

Special targeting system for viral vectors

C12N2710/10351

Methods of production or purification of viral material

C12N2710/10352

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/10361

Methods of inactivation or attenuation

C12N2710/10362

by genetic engineering

C12N2710/10363

by chemical treatment

C12N2710/10364

by serial passage

C12N2710/10371

Demonstrated in vivo effect

C12N2710/10388

for redistribution

C12N2710/12011

Asfarviridae

C12N2710/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/12023

Virus like particles [VLP]

C12N2710/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/12041

Use of virus, viral particle or viral elements as a vector

C12N2710/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/12043

viral genome or elements thereof as genetic vector

C12N2710/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/12045

Special targeting system for viral vectors

C12N2710/12051

Methods of production or purification of viral material

C12N2710/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/12061

Methods of inactivation or attenuation

C12N2710/12062

by genetic engineering

C12N2710/12063

by chemical treatment

C12N2710/12064

by serial passage

C12N2710/12071

Demonstrated in vivo effect

C12N2710/12088

for redistribution

C12N2710/14011

Baculoviridae

C12N2710/14021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/14022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/14023

Virus like particles [VLP]

C12N2710/14031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/14032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/14033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/14034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/14041

Use of virus, viral particle or viral elements as a vector

C12N2710/14042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/14043

viral genome or elements thereof as genetic vectore

C12N2710/14044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/14045

Special targeting system for viral vectors

C12N2710/14051

Methods of production or purification of viral material

C12N2710/14052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/14061

Methods of inactivation or attenuation

C12N2710/14062

by genetic engineering

C12N2710/14063

by chemical treatment

C12N2710/14064

by serial passage

C12N2710/14071

Demonstrated in vivo effect

C12N2710/14088

for redistribution

C12N2710/14111

Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus

C12N2710/14121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/14122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/14123

Virus like particles [VLP]

C12N2710/14131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/14132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/14133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/14134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/14141

Use of virus, viral particle or viral elements as a vector

C12N2710/14142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/14143

viral genome or elements thereof as genetic vector

C12N2710/14144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/14145

Special targeting system for viral vectors

C12N2710/14151

Methods of production or purification of viral material

C12N2710/14152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/14161

Methods of inactivation or attenuation

C12N2710/14162

by genetic engineering

C12N2710/14163

by chemical treatment

C12N2710/14164

by serial passage

C12N2710/14171

Demonstrated in vivo effect

C12N2710/14188

For redistribution

C12N2710/16011

Herpesviridae

C12N2710/16021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/16022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/16023

Virus like particles [VLP]

C12N2710/16031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/16032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/16033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/16034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/16041

Use of virus, viral particle or viral elements as a vector

C12N2710/16042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/16043

viral genome or elements thereof as genetic vector

C12N2710/16044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/16045

Special targeting system for viral vectors

C12N2710/16051

Methods of production or purification of viral material

C12N2710/16052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/16061

Methods of inactivation or attenuation

C12N2710/16062

by genetic engineering

C12N2710/16063

by chemical treatment

C12N2710/16064

by serial passage

C12N2710/16071

Demonstrated in vivo effect

C12N2710/16088

for redistribution

C12N2710/16111

Cytomegalovirus, e.g. human herpesvirus 5

C12N2710/16121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/16122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/16123

Virus like particles [VLP]

C12N2710/16131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/16132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/16133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/16134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/16141

Use of virus, viral particle or viral elements as a vector

C12N2710/16142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/16143

viral genome or elements thereof as genetic vector

C12N2710/16144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/16145

Special targeting system for viral vectors

C12N2710/16151

Methods of production or purification of viral material

C12N2710/16152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/16161

Methods of inactivation or attenuation

C12N2710/16162

by genetic engineering

C12N2710/16163

by chemical treatment

C12N2710/16164

by serial passage

C12N2710/16171

Demonstrated in vivo effect

C12N2710/16188

for redistribution

C12N2710/16211

Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus

C12N2710/16221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/16222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/16223

Virus like particles [VLP]

C12N2710/16231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/16232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/16233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/16234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/16241

Use of virus, viral particle or viral elements as a vector

C12N2710/16242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/16243

viral genome or elements thereof as genetic vector

C12N2710/16244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/16245

Special targeting system for viral vectors

C12N2710/16251

Methods of production or purification of viral material

C12N2710/16252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/16261

Methods of inactivation or attenuation

C12N2710/16262

by genetic engineering

C12N2710/16263

by chemical treatment

C12N2710/16264

by serial passage

C12N2710/16271

Demonstrated in vivo effect

C12N2710/16288

for redistribution

C12N2710/16311

Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV

C12N2710/16321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/16322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/16323

Virus like particles [VLP]

C12N2710/16331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/16332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/16333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/16334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/16341

Use of virus, viral particle or viral elements as a vector

C12N2710/16342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/16343

viral genome or elements thereof as genetic vector

C12N2710/16344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/16345

Special targeting system for viral vectors

C12N2710/16351

Methods of production or purification of viral material

C12N2710/16352

relating to complementin g cells and packaging systems for producing virus or viral particles

C12N2710/16361

Methods of inactivation or attenuation

C12N2710/16362

by genetic engineering

C12N2710/16363

by chemical treatment

C12N2710/16364

by serial passage

C12N2710/16371

Demonstrated in vivo effect

C12N2710/16388

for redistribution

C12N2710/16411

Rhadinovirus, e.g. human herpesvirus 8

C12N2710/16421

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/16422

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/16423

Virus like particles [VLP]

C12N2710/16431

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/16432

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/16433

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/16434

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/16441

Use of virus, viral particle or viral elements as a vector

C12N2710/16442

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/16443

viral genome or elements thereof as genetic vector

C12N2710/16444

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/16445

Special targeting system for viral vectors

C12N2710/16451

Methods of production or purification of viral material

C12N2710/16452

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/16461

Methods of inactivation or attenuation

C12N2710/16462

by genetic engineering

C12N2710/16463

by chemical treatment

C12N2710/16464

by serial passage

C12N2710/16471

Demonstrated in vivo effect

C12N2710/16488

for redistribution

C12N2710/16511

Roseolovirus, e.g. human herpesvirus 6, 7

C12N2710/16521

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/16522

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/16523

Virus like particles [VLP]

C12N2710/16531

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/16532

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/16533

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/16534

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral

C12N2710/16541

Use of virus, viral particle or viral elements as a vector

C12N2710/16542

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/16543

viral genome or elements thereof as genetic vector

C12N2710/16544

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/16545

Special targeting system for viral vectors

C12N2710/16551

Methods of production or purification of viral material

C12N2710/16552

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/16561

Methods of inactivation or attenuation

C12N2710/16562

by genetic engineering

C12N2710/16563

by chemical treatment

C12N2710/16564

by serial passage

C12N2710/16571

Demonstrated in vivo effect

C12N2710/16588

for redistribution

C12N2710/16611

Simplexvirus, e.g. human herpesvirus 1, 2

C12N2710/16621

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/16622

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/16623

Virus like particles [VLP]

C12N2710/16631

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/16632

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/16633

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/16634

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/16641

Use of virus, viral particle or viral elements as a vector

C12N2710/16642

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/16643

viral genome or elements thereof as genetic vector

C12N2710/16644

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/16645

Special targeting system for viral vectors

C12N2710/16651

Methods of production or purification of viral material

C12N2710/16652

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/16661

Methods of inactivation or attenuation

C12N2710/16662

by genetic engineering

C12N2710/16663

by chemical treatment

C12N2710/16664

by serial passage

C12N2710/16671

Demonstrated in vivo effect

C12N2710/16688

for redistribution

C12N2710/16711

Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies

C12N2710/16721

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/16722

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/16723

Virus like particles [VLP]

C12N2710/16731

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/16732

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/16733

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/16734

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/16741

Use of virus, viral particle or viral elements as a vector

C12N2710/16742

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/16743

viral genome or elements thereof as genetic vector

C12N2710/16744

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/16745

Special targeting system for viral vectors

C12N2710/16751

Methods of production or purification of viral material

C12N2710/16752

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/16761

Methods of inactivation or attenuation

C12N2710/16762

by genetic engineering

C12N2710/16763

by chemical treatment

C12N2710/16764

by serial passage

C12N2710/16771

Demonstrated in vivo effect

C12N2710/16788

for redistribution

C12N2710/18011

Nimaviridae

C12N2710/18021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/18022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/18023

Virus like particles [VLP]

C12N2710/18031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/18032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/18033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/18034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/18041

Use of virus, viral particle or viral elements as a vector

C12N2710/18042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/18043

viral genome or elements thereof as genetic vector

C12N2710/18044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/18045

Special targeting system for viral vectors

C12N2710/18051

Methods of production or purification of viral material

C12N2710/18052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/18061

Methods of inactivation or attenuation

C12N2710/18062

by genetic engineering

C12N2710/18063

by chemical treatment

C12N2710/18064

by serial passage

C12N2710/18071

Demonstrated in vivo effect

C12N2710/18088

for redistribution

C12N2710/20011

Papillomaviridae

C12N2710/20021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/20022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/20023

Virus like particles [VLP]

C12N2710/20031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/20032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/20033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/20034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/20041

Use of virus, viral particle or viral elements as a vector

C12N2710/20042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/20043

viral genome or elements thereof as genetic vector

C12N2710/20044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/20045

Special targeting system for viral vectors

C12N2710/20051

Methods of production or purification of viral material

C12N2710/20052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/20061

Methods of inactivation or attenuation

C12N2710/20062

by genetic engineering

C12N2710/20063

by chemical treatment

C12N2710/20064

by serial passage

C12N2710/20071

Demonstrated in vivo effect

C12N2710/20088

for redistribution

C12N2710/22011

Polyomaviridae, e.g. polyoma, SV40, JC

C12N2710/22021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/22022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/22023

Virus like particles [VLP]

C12N2710/22031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/22032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/22033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/22034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/22041

Use of virus, viral particle or viral elements as a vector

C12N2710/22042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/22043

viral genome or elements thereof as genetic vector

C12N2710/22044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/22045

Special targeting system for viral vectors

C12N2710/22051

Methods of production or purification of viral material

C12N2710/22052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/22061

Methods of inactivation or attenuation

C12N2710/22062

by genetic engineering

C12N2710/22063

by chemical treatment

C12N2710/22064

by serial passage

C12N2710/22071

Demonstrated in vivo effect

C12N2710/22088

for redistribution

C12N2710/24011

Poxviridae

C12N2710/24021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/24022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/24023

Virus like particles [VLP]

C12N2710/24031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/24032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/24033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/24034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/24041

Use of virus, viral particle or viral elements as a vector

C12N2710/24042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/24043

viral genome or elements thereof as genetic vector

C12N2710/24044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/24045

Special targeting system for viral vectors

C12N2710/24051

Methods of production or purification of viral material

C12N2710/24052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/24061

Methods of inactivation or attenuation

C12N2710/24062

by genetic engineering

C12N2710/24063

by chemical treatment

C12N2710/24064

by serial passage

C12N2710/24071

Demonstrated in vivo effect

C12N2710/24088

for redistribution

C12N2710/24111

Orthopoxvirus, e.g. vaccinia virus, variola

C12N2710/24121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/24122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/24123

Virus like particles [VLP]

C12N2710/24131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/24132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/24133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/24134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/24141

Use of virus, viral particle or viral elements as a vector

C12N2710/24142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/24143

viral genome or elements thereof as genetic vector

C12N2710/24144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/24145

Special targeting system for viral vectors

C12N2710/24151

Methods of production or purification of viral material

C12N2710/24152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/24161

Methods of inactivation or attenuation

C12N2710/24162

by genetic engineering

C12N2710/24163

by chemical treatment

C12N2710/24164

by serial passage

C12N2710/24171

Demonstrated in vivo effect

C12N2710/24188

for redistribution

C12N2710/24211

Parapoxvirus, e.g. Orf virus

C12N2710/24221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2710/24222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2710/24223

Virus like particles [VLP]

C12N2710/24231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2710/24232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2710/24233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2710/24234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2710/24241

Use of virus, viral particle or viral elements as a vector

C12N2710/24242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2710/24243

viral genome or elements thereof as genetic vector

C12N2710/24244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2710/24245

Special targeting system for viral vectors

C12N2710/24251

Methods of production or purification of viral material

C12N2710/24252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2710/24261

Methods of inactivation or attenuation

C12N2710/24262

by genetic engineering

C12N2710/24263

by chemical treatment

C12N2710/24264

by serial passage

C12N2710/24271

Demonstrated in vivo effect

C12N2710/24288

for redistribution

C12N2720/00

dsRNA viruses

C12N2720/00011

Details

C12N2720/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2720/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2720/00023

Virus like particles [VLP]

C12N2720/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2720/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2720/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2720/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2720/00041

Use of virus, viral particle or viral elements as a vector

C12N2720/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2720/00043

viral genome or elements thereof as genetic vector

C12N2720/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2720/00045

Special targeting system for viral vectors

C12N2720/00051

Methods of production or purification of viral material

C12N2720/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2720/00061

Methods of inactivation or attenuation

C12N2720/00062

by genetic engineering

C12N2720/00063

by chemical treatment

C12N2720/00064

by serial passage

C12N2720/00071

Demonstrated in vivo effect

C12N2720/00088

for redistribution

C12N2720/10011

Birnaviridae

C12N2720/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2720/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2720/10023

Virus like particles [VLP]

C12N2720/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2720/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2720/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2720/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2720/10041

Use of virus, viral particle or viral elements as a vector

C12N2720/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2720/10043

viral genome or elements thereof as genetic vector

C12N2720/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2720/10045

Special targeting system for viral vectors

C12N2720/10051

Methods of production or purification of viral material

C12N2720/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2720/10061

Methods of inactivation or attenuation

C12N2720/10062

by genetic engineering

C12N2720/10063

by chemical treatment

C12N2720/10064

by serial passage

C12N2720/10071

Demonstrated in vivo effect

C12N2720/10088

for redistribution

C12N2720/12011

Reoviridae

C12N2720/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2720/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2720/12023

Virus like particles [VLP]

C12N2720/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2720/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2720/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2720/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2720/12041

Use of virus, viral particle or viral elements as a vector

C12N2720/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2720/12043

viral genome or elements thereof as genetic vector

C12N2720/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2720/12045

Special targeting system for viral vectors

C12N2720/12051

Methods of production or purification of viral material

C12N2720/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2720/12061

Methods of inactivation or attenuation

C12N2720/12062

by genetic engineering

C12N2720/12063

by chemical treatment

C12N2720/12064

by serial passage

C12N2720/12071

Demonstrated in vivo effect

C12N2720/12088

for redistribution

C12N2720/12111

Orbivirus, e.g. bluetongue virus

C12N2720/12121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2720/12122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2720/12123

Virus like particles [VLP]

C12N2720/12131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2720/12132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2720/12133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2720/12134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2720/12141

Use of virus, viral particle or viral elements as a vector

C12N2720/12142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2720/12143

viral genome or elements thereof as genetic vector

C12N2720/12144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2720/12145

Special targeting system for viral vectors

C12N2720/12151

Methods of production or purification of viral material

C12N2720/12152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2720/12161

Methods of inactivation or attenuation

C12N2720/12162

by genetic engineering

C12N2720/12163

by chemical treatment

C12N2720/12164

by serial passage

C12N2720/12171

Demonstrated in vivo effect

C12N2720/12188

for redistribution

C12N2720/12211

Orthoreovirus, e.g. mammalian orthoreovirus

C12N2720/12221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2720/12222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2720/12223

Virus like particles [VLP]

C12N2720/12231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2720/12232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2720/12233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2720/12234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2720/12241

Use of virus, viral particle or viral elements as a vector

C12N2720/12242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2720/12243

viral genome or elements thereof as genetic vector

C12N2720/12244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2720/12245

Special targeting system for viral vectors

C12N2720/12251

Methods of production or purification of viral material

C12N2720/12252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2720/12261

Methods of inactivation or attenuation

C12N2720/12262

by genetic engineering

C12N2720/12263

by chemical treatment

C12N2720/12264

by serial passage

C12N2720/12271

Demonstrated in vivo effect

C12N2720/12288

for redistribution

C12N2720/12311

Rotavirus, e.g. rotavirus A

C12N2720/12321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2720/12322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2720/12323

Virus like particles [VLP]

C12N2720/12331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2720/12332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2720/12333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2720/12334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2720/12341

Use of virus, viral particle or viral elements as a vector

C12N2720/12342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2720/12343

viral genome or elements thereof as genetic vector

C12N2720/12344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2720/12345

Special targeting system for viral vectors

C12N2720/12351

Methods of production or purification of viral material

C12N2720/12352

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2720/12361

Methods of inactivation or attenuation

C12N2720/12362

by genetic engineering

C12N2720/12363

by chemical treatment

C12N2720/12364

by serial passage

C12N2720/12371

Demonstrated in vivo effect

C12N2720/12388

for redistribution

C12N2730/00

Reverse transcribing DNA viruses

C12N2730/00011

Details

C12N2730/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2730/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2730/00023

Virus like particles [VLP]

C12N2730/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2730/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2730/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2730/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2730/00041

Use of virus, viral particle or viral elements as a vector

C12N2730/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2730/00043

viral genome or elements thereof as genetic vector

C12N2730/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2730/00045

Special targeting system for viral vectors

C12N2730/00051

Methods of production or purification of viral material

C12N2730/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2730/00061

Methods of inactivation or attenuation

C12N2730/00062

by genetic engineering

C12N2730/00063

by chemical treatment

C12N2730/00064

by serial passage

C12N2730/00071

Demonstrated in vivo effect

C12N2730/00088

for redistribution

C12N2730/10011

Hepadnaviridae

C12N2730/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2730/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2730/10023

Virus like particles [VLP]

C12N2730/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2730/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2730/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2730/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2730/10041

Use of virus, viral particle or viral elements as a vector

C12N2730/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2730/10043

viral genome or elements thereof as genetic vector

C12N2730/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2730/10045

Special targeting system for viral vectors

C12N2730/10051

Methods of production or purification of viral material

C12N2730/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2730/10061

Methods of inactivation or attenuation

C12N2730/10062

by genetic engineering

C12N2730/10063

by chemical treatment

C12N2730/10064

by serial passage

C12N2730/10071

Demonstrated in vivo effect

C12N2730/10088

for redistribution

C12N2730/10111

Orthohepadnavirus, e.g. hepatitis B virus

C12N2730/10121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2730/10122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2730/10123

Virus like particles [VLP]

C12N2730/10131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2730/10132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2730/10133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2730/10134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2730/10141

Use of virus, viral particle or viral elements as a vector

C12N2730/10142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2730/10143

viral genome or elements thereof as genetic vector

C12N2730/10144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2730/10145

Special targeting system for viral vectors

C12N2730/10151

Methods of production or purification of viral material

C12N2730/10152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2730/10161

Methods of inactivation or attenuation

C12N2730/10162

by genetic engineering

C12N2730/10163

by chemical treatment

C12N2730/10164

by serial passage

C12N2730/10171

Demonstrated in vivo effect

C12N2730/10188

for redistribution

C12N2740/00

Reverse transcribing RNA viruses

C12N2740/00011

Details

C12N2740/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/00023

Virus like particles [VLP]

C12N2740/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/00041

Use of virus, viral particle or viral elements as a vector

C12N2740/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/00043

viral genome or elements thereof as genetic vector

C12N2740/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/00045

Special targeting system for viral vectors

C12N2740/00051

Methods of production or purification of viral material

C12N2740/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/00061

Methods of inactivation or attenuation

C12N2740/00062

by genetic engineering

C12N2740/00063

by chemical treatment

C12N2740/00064

by serial passage

C12N2740/00071

Demonstrated in vivo effect

C12N2740/00088

for redistribution

C12N2740/10011

Retroviridae

C12N2740/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/10023

Virus like particles [VLP]

C12N2740/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/10041

Use of virus, viral particle or viral elements as a vector

C12N2740/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/10043

viral genome or elements thereof as genetic vector

C12N2740/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/10045

Special targeting system for viral vectors

C12N2740/10051

Methods of production or purification of viral material

C12N2740/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/10061

Methods of inactivation or attenuation

C12N2740/10062

by genetic engineering

C12N2740/10063

by chemical treatment

C12N2740/10064

by serial passage

C12N2740/10071

Demonstrated in vivo effect

C12N2740/10088

for redistribution

C12N2740/11011

Alpharetrovirus, e.g. avian leucosis virus

C12N2740/11021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/11022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/11023

Virus like particles [VLP]

C12N2740/11031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/11032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/11033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/11034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/11041

Use of virus, viral particle or viral elements as a vector

C12N2740/11042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/11043

viral genome or elements thereof as genetic vector

C12N2740/11044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/11045

Special targeting system for viral vectors

C12N2740/11051

Methods of production or purification of viral material

C12N2740/11052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/11061

Methods of inactivation or attenuation

C12N2740/11062

by genetic engineering

C12N2740/11063

by chemical treatment

C12N2740/11064

by serial passage

C12N2740/11071

Demonstrated in vivo effect

C12N2740/11088

for redistribution

C12N2740/12011

Betaretrovirus, e.g. mouse mammary tumour virus

C12N2740/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/12023

Virus like particles [VLP]

C12N2740/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/12041

Use of virus, viral particle or viral elements as a vector

C12N2740/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/12043

viral genome or elements thereof as genetic vector

C12N2740/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/12045

Special targeting system for viral vectors

C12N2740/12051

Methods of production or purification of viral material

C12N2740/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/12061

Methods of inactivation or attenuation

C12N2740/12062

by genetic engineering

C12N2740/12063

by chemical treatment

C12N2740/12064

by serial passage

C12N2740/12071

Demonstrated in vivo effect

C12N2740/12088

for redistribution

C12N2740/13011

Gammaretrovirus, e.g. murine leukeamia virus

C12N2740/13021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/13022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/13023

Virus like particles [VLP]

C12N2740/13031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/13032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/13033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/13034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/13041

Use of virus, viral particle or viral elements as a vector

C12N2740/13042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/13043

viral genome or elements thereof as genetic vector

C12N2740/13044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/13045

Special targeting system for viral vectors

C12N2740/13051

Methods of production or purification of viral material

C12N2740/13052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/13061

Methods of inactivation or attenuation

C12N2740/13062

by genetic engineering

C12N2740/13063

by chemical treatment

C12N2740/13064

by serial passage

C12N2740/13071

Demonstrated in vivo effect

C12N2740/13088

for redistribution

C12N2740/14011

Deltaretrovirus, e.g. bovine leukeamia virus

C12N2740/14021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/14022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/14023

Virus like particles [VLP]

C12N2740/14031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/14032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/14033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/14034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/14041

Use of virus, viral particle or viral elements as a vector

C12N2740/14042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/14043

viral genome or elements thereof as genetic vector

C12N2740/14044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/14045

Special targeting system for viral vectors

C12N2740/14051

Methods of production or purification of viral material

C12N2740/14052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/14061

Methods of inactivation or attenuation

C12N2740/14062

by genetic engineering

C12N2740/14063

by chemical treatment

C12N2740/14064

by serial passage

C12N2740/14071

Demonstrated in vivo effect

C12N2740/14088

for redistribution

C12N2740/15011

Lentivirus, not HIV, e.g. FIV, SIV

C12N2740/15021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/15022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/15023

Virus like particles [VLP]

C12N2740/15031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/15032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/15033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/15034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/15041

Use of virus, viral particle or viral elements as a vector

C12N2740/15042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/15043

viral genome or elements thereof as genetic vector

C12N2740/15044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/15045

Special targeting system for viral vectors

C12N2740/15051

Methods of production or purification of viral material

C12N2740/15052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/15061

Methods of inactivation or attenuation

C12N2740/15062

by genetic engineering

C12N2740/15063

by chemical treatment

C12N2740/15064

by serial passage

C12N2740/15071

Demonstrated in vivo effect

C12N2740/15088

for redistribution

C12N2740/16011

Human Immunodeficiency Virus, HIV

C12N2740/16021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/16022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/16023

Virus like particles [VLP]

C12N2740/16031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/16032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/16033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/16034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/16041

Use of virus, viral particle or viral elements as a vector

C12N2740/16042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/16043

viral genome or elements thereof as genetic vector

C12N2740/16044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/16045

Special targeting system for viral vectors

C12N2740/16051

Methods of production or purification of viral material

C12N2740/16052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/16061

Methods of inactivation or attenuation

C12N2740/16062

by genetic engineering

C12N2740/16063

by chemical treatment

C12N2740/16064

by serial passage

C12N2740/16071

Demonstrated in vivo effect

C12N2740/16088

for redistribution

C12N2740/16111

concerning HIV env

C12N2740/16122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/16134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/16171

Demonstrated in vivo effect

C12N2740/16188

for redistribution

C12N2740/16211

concerning HIV gagpol

C12N2740/16222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/16234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/16271

Demonstrated in vivo effect

C12N2740/16288

for redistribution

C12N2740/16311

concerning HIV regulatory proteins

C12N2740/16322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/16334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/16371

Demonstrated in vivo effect

C12N2740/16388

for redistribution

C12N2740/17011

Spumavirus, e.g. chimpanzee foamy virus

C12N2740/17021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2740/17022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2740/17023

Virus like particles [VLP]

C12N2740/17031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2740/17032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2740/17033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2740/17034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2740/17041

Use of virus, viral particle or viral elements as a vector

C12N2740/17042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2740/17043

viral genome or elements thereof as genetic vector

C12N2740/17044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2740/17045

Special targeting system for viral vectors

C12N2740/17051

Methods of production or purification of viral material

C12N2740/17052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2740/17061

Methods of inactivation or attenuation

C12N2740/17062

by genetic engineering

C12N2740/17063

by chemical treatment

C12N2740/17064

by serial passage

C12N2740/17071

Demonstrated in vivo effect

C12N2740/17088

for redistribution

C12N2750/00

ssDNA viruses

C12N2750/00011

Details

C12N2750/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2750/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2750/00023

Virus like particles [VLP]

C12N2750/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2750/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2750/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2750/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2750/00041

Use of virus, viral particle or viral elements as a vector

C12N2750/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2750/00043

viral genome or elements thereof as genetic vector

C12N2750/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2750/00045

Special targeting system for viral vectors

C12N2750/00051

Methods of production or purification of viral material

C12N2750/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2750/00061

Methods of inactivation or attenuation

C12N2750/00062

by genetic engineering

C12N2750/00063

by chemical treatment

C12N2750/00064

by serial passage

C12N2750/00071

Demonstrated in vivo effect

C12N2750/00088

for redistribution

C12N2750/10011

Circoviridae

C12N2750/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2750/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2750/10023

Virus like particles [VLP]

C12N2750/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2750/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2750/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2750/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2750/10041

Use of virus, viral particle or viral elements as a vector

C12N2750/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2750/10043

viral genome or elements thereof as genetic vector

C12N2750/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2750/10045

Special targeting system for viral vectors

C12N2750/10051

Methods of production or purification of viral material

C12N2750/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2750/10061

Methods of inactivation or attenuation

C12N2750/10062

by genetic engineering

C12N2750/10063

by chemical treatment

C12N2750/10064

by serial passage

C12N2750/10071

Demonstrated in vivo effect

C12N2750/10088

for redistribution

C12N2750/12011

Geminiviridae

C12N2750/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2750/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2750/12023

Virus like particles [VLP]

C12N2750/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2750/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2750/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2750/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2750/12041

Use of virus, viral particle or viral elements as a vector

C12N2750/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2750/12043

viral genome or elements thereof as genetic vector

C12N2750/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2750/12045

Special targeting system for viral vectors

C12N2750/12051

Methods of production or purification of viral material

C12N2750/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2750/12061

Methods of inactivation or attenuation

C12N2750/12062

by genetic engineering

C12N2750/12063

by chemical treatment

C12N2750/12064

by serial passage

C12N2750/12071

Demonstrated in vivo effect

C12N2750/12088

for redistribution

C12N2750/14011

Parvoviridae

C12N2750/14021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2750/14022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2750/14023

Virus like particles [VLP]

C12N2750/14031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2750/14032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2750/14033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2750/14034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2750/14041

Use of virus, viral particle or viral elements as a vector

C12N2750/14042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2750/14043

viral genome or elements thereof as genetic vector

C12N2750/14044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2750/14045

Special targeting system for viral vectors

C12N2750/14051

Methods of production or purification of viral material

C12N2750/14052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2750/14061

Methods of inactivation or attenuation

C12N2750/14062

by genetic engineering

C12N2750/14063

by chemical treatment

C12N2750/14064

by serial passage

C12N2750/14071

Demonstrated in vivo effect

C12N2750/14088

for redistribution

C12N2750/14111

Dependovirus, e.g. adenoassociated viruses

C12N2750/14121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2750/14122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2750/14123

Virus like particles [VLP]

C12N2750/14131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2750/14132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2750/14133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2750/14134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2750/14141

Use of virus, viral particle or viral elements as a vector

C12N2750/14142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2750/14143

viral genome or elements thereof as genetic vector

C12N2750/14144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2750/14145

Special targeting system for viral vectors

C12N2750/14151

Methods of production or purification of viral material

C12N2750/14152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2750/14161

Methods of inactivation or attenuation

C12N2750/14162

by genetic engineering

C12N2750/14163

by chemical treatment

C12N2750/14164

by serial passage

C12N2750/14171

Demonstrated in vivo effect

C12N2750/14188

for redistribution

C12N2750/14211

Erythrovirus, e.g. B19 virus

C12N2750/14221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2750/14222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2750/14223

Virus like particles [VLP]

C12N2750/14231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2750/14232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2750/14233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2750/14234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2750/14241

Use of virus, viral particle or viral elements as a vector

C12N2750/14242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2750/14243

viral genome or elements thereof as genetic vector

C12N2750/14244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2750/14245

Special targeting system for viral vectors

C12N2750/14251

Methods of production or purification of viral material

C12N2750/14252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2750/14261

Methods of inactivation or attenuation

C12N2750/14262

by genetic engineering

C12N2750/14263

by chemical treatment

C12N2750/14264

by serial passage

C12N2750/14271

Demonstrated in vivo effect

C12N2750/14288

for redistribution

C12N2750/14311

Parvovirus, e.g. minute virus of mice

C12N2750/14321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2750/14322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2750/14323

Virus like particles [VLP]

C12N2750/14331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2750/14332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2750/14333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2750/14334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2750/14341

Use of virus, viral particle or viral elements as a vector

C12N2750/14342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2750/14343

viral genome or elements thereof as genetic vector

C12N2750/14344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2750/14345

Special targeting system for viral vectors

C12N2750/14351

Methods of production or purification of viral material

C12N2750/14352

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2750/14361

Methods of inactivation or attenuation

C12N2750/14362

by genetic engineering

C12N2750/14363

by chemical treatment

C12N2750/14364

by serial passage

C12N2750/14371

Demonstrated in vivo effect

C12N2750/14388

for redistribution

C12N2760/00

ssRNA viruses negative-sense

C12N2760/00011

Details

C12N2760/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/00023

Virus like particles [VLP]

C12N2760/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/00041

Use of virus, viral particle or viral elements as a vector

C12N2760/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/00043

viral genome or elements thereof as genetic vector

C12N2760/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/00045

Special targeting system for viral vectors

C12N2760/00051

Methods of production or purification of viral material

C12N2760/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/00061

Methods of inactivation or attenuation

C12N2760/00062

by genetic engineering

C12N2760/00063

by chemical treatment

C12N2760/00064

by serial passage

C12N2760/00071

Demonstrated in vivo effect

C12N2760/00088

for redistribution

C12N2760/10011

Arenaviridae

C12N2760/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/10023

Virus like particles [VLP]

C12N2760/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/10041

Use of virus, viral particle or viral elements as a vector

C12N2760/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/10043

viral genome or elements thereof as genetic vector

C12N2760/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/10045

Special targeting system for viral vectors

C12N2760/10051

Methods of production or purification of viral material

C12N2760/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/10061

Methods of inactivation or attenuation

C12N2760/10062

by genetic engineering

C12N2760/10063

by chemical treatment

C12N2760/10064

by serial passage

C12N2760/10071

Demonstrated in vivo effect

C12N2760/10088

for redistribution

C12N2760/10111

Deltavirus, e.g. hepatitis delta virus

C12N2760/10121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/10122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/10123

Virus like particles [VLP]

C12N2760/10131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/10132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/10133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/10134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/10141

Use of virus, viral particle or viral elements as a vector

C12N2760/10142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/10143

viral genome or elements thereof as genetic vector

C12N2760/10144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/10145

Special targeting system for viral vectors

C12N2760/10151

Methods of production or purification of viral material

C12N2760/10152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/10161

Methods of inactivation or attenuation

C12N2760/10162

by genetic engineering

C12N2760/10163

by chemical treatment

C12N2760/10164

by serial passage

C12N2760/10171

Demonstrated in vivo effect

C12N2760/10188

for redistribution

C12N2760/12011

Bunyaviridae

C12N2760/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/12023

Virus like particles [VLP]

C12N2760/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/12041

Use of virus, viral particle or viral elements as a vector

C12N2760/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/12043

viral genome or elements thereof as genetic vector

C12N2760/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/12045

Special targeting system for viral vectors

C12N2760/12051

Methods of production or purification of viral material

C12N2760/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/12061

Methods of inactivation or attenuation

C12N2760/12062

by genetic engineering

C12N2760/12063

by chemical treatment

C12N2760/12064

by serial passage

C12N2760/12071

Demonstrated in vivo effect

C12N2760/12088

for redistribution

C12N2760/12111

Hantavirus, e.g. Hantaan virus

C12N2760/12121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/12122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/12123

Virus like particles [VLP]

C12N2760/12131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/12132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/12133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/12134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/12141

Use of virus, viral particle or viral elements as a vector

C12N2760/12142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/12143

viral genome or elements thereof as genetic vector

C12N2760/12144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/12145

Special targeting system for viral vectors

C12N2760/12151

Methods of production or purification of viral material

C12N2760/12152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/12161

Methods of inactivation or attenuation

C12N2760/12162

by genetic engineering

C12N2760/12163

by chemical treatment

C12N2760/12164

by serial passage

C12N2760/12171

Demonstrated in vivo effect

C12N2760/12188

for redistribution

C12N2760/12211

Phlebovirus, e.g. Rift Valley fever virus

C12N2760/12221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/12222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/12223

Virus like particles [VLP]

C12N2760/12231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/12232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/12233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/12234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/12241

Use of virus, viral particle or viral elements as a vector

C12N2760/12242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/12243

viral genome or elements thereof as genetic vector

C12N2760/12244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/12245

Special targeting system for viral vectors

C12N2760/12251

Methods of production or purification of viral material

C12N2760/12252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/12261

Methods of inactivation or attenuation

C12N2760/12262

by genetic engineering

C12N2760/12263

by chemical treatment

C12N2760/12264

by serial passage

C12N2760/12271

Demonstrated in vivo effect

C12N2760/12288

for redistribution

C12N2760/14011

Filoviridae

C12N2760/14021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/14022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/14023

Virus like particles [VLP]

C12N2760/14031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/14032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/14033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/14034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/14041

Use of virus, viral particle or viral elements as a vector

C12N2760/14042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/14043

viral genome or elements thereof as genetic vector

C12N2760/14044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/14045

Special targeting system for viral vectors

C12N2760/14051

Methods of production or purification of viral material

C12N2760/14052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/14061

Methods of inactivation or attenuation

C12N2760/14062

by genetic engineering

C12N2760/14063

by chemical treatment

C12N2760/14064

by serial passage

C12N2760/14071

Demonstrated in vivo effect

C12N2760/14088

for redistribution

C12N2760/14111

Ebolavirus, e.g. Zaire ebolavirus

C12N2760/14121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/14122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/14123

Virus like particles [VLP]

C12N2760/14131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/14132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/14133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/14134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/14141

Use of virus, viral particle or viral elements as a vector

C12N2760/14142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/14143

viral genome or elements thereof as genetic vector

C12N2760/14144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/14145

Special targeting system for viral vectors

C12N2760/14151

Methods of production or purification of viral material

C12N2760/14152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/14161

Methods of inactivation or attenuation

C12N2760/14162

by genetic engineering

C12N2760/14163

by chemical treatment

C12N2760/14164

by serial passage

C12N2760/14171

Demonstrated in vivo effect

C12N2760/14188

for redistribution

C12N2760/14211

Marburgvirus, e.g. lake Victoria marburgvirus

C12N2760/14221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/14222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/14223

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/14231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/14232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/14233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/14234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/14241

Use of virus, viral particle or viral elements as a vector

C12N2760/14242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/14243

viral genome or elements thereof as genetic vector

C12N2760/14244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/14245

Special targeting system for viral vectors

C12N2760/14251

Methods of production or purification of viral material

C12N2760/14252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/14261

Methods of inactivation or attenuation

C12N2760/14262

by genetic engineering

C12N2760/14263

by chemical treatment

C12N2760/14264

by serial passage

C12N2760/14271

Demonstrated in vivo effect

C12N2760/14288

for redistribution

C12N2760/16011

Orthomyxoviridae

C12N2760/16021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/16022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/16023

Virus like particles [VLP]

C12N2760/16031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/16032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/16033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/16034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/16041

Use of virus, viral particle or viral elements as a vector

C12N2760/16042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/16043

viral genome or elements thereof as genetic vector

C12N2760/16044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/16045

Special targeting system for viral vectors

C12N2760/16051

Methods of production or purification of viral material

C12N2760/16052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/16061

Methods of inactivation or attenuation

C12N2760/16062

by genetic engineering

C12N2760/16063

by chemical treatment

C12N2760/16064

by serial passage

C12N2760/16071

Demonstrated in vivo effect

C12N2760/16088

for redistribution

C12N2760/16111

Influenzavirus A, i.e. influenza A virus

C12N2760/16121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/16122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/16123

Virus like particles [VLP]

C12N2760/16131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/16132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/16133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/16134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/16141

Use of virus, viral particle or viral elements as a vector

C12N2760/16142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/16143

viral genome or elements thereof as genetic vector

C12N2760/16144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/16145

Special targeting system for viral vectors

C12N2760/16151

Methods of production or purification of viral material

C12N2760/16152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/16161

Methods of inactivation or attenuation

C12N2760/16162

by genetic engineering

C12N2760/16163

by chemical treatment

C12N2760/16164

by serial passage

C12N2760/16171

Demonstrated in vivo effect

C12N2760/16188

for redistribution

C12N2760/16211

Influenzavirus B, i.e. influenza B virus

C12N2760/16221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/16222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/16223

Virus like particles [VLP]

C12N2760/16231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/16232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/16233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/16234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/16241

Use of virus, viral particle or viral elements as a vector

C12N2760/16242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/16243

viral genome or elements thereof as genetic vector

C12N2760/16244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/16245

Special targeting system for viral vectors

C12N2760/16251

Methods of production or purification of viral material

C12N2760/16252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/16261

Methods of inactivation or attenuation

C12N2760/16262

by genetic engineering

C12N2760/16263

by chemical treatment

C12N2760/16264

by serial passage

C12N2760/16271

Demonstrated in vivo effect

C12N2760/16288

for redistribution

C12N2760/16311

Influenzavirus C, i.e. influenza C virus

C12N2760/16321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/16322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/16323

Virus like particles [VLP]

C12N2760/16331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/16332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/16333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/16334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/16341

Use of virus, viral particle or viral elements as a vector

C12N2760/16342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/16343

viral genome or elements thereof as genetic vector

C12N2760/16344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/16345

Special targeting system for viral vectors

C12N2760/16351

Methods of production or purification of viral material

C12N2760/16352

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/16361

Methods of inactivation or attenuation

C12N2760/16362

by genetic engineering

C12N2760/16363

by chemical treatment

C12N2760/16364

by serial passage

C12N2760/16371

Demonstrated in vivo effect

C12N2760/16388

for redistribution

C12N2760/18011

Paramyxoviridae

C12N2760/18021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18023

Virus like particles [VLP]

C12N2760/18031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18041

Use of virus, viral particle or viral elements as a vector

C12N2760/18042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18043

viral genome or elements thereof as genetic vector

C12N2760/18044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/18045

Special targeting system for viral vectors

C12N2760/18051

Methods of production or purification of viral material

C12N2760/18052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18061

Methods of inactivation or attenuation

C12N2760/18062

by genetic engineering

C12N2760/18063

by chemical treatment

C12N2760/18064

by serial passage

C12N2760/18071

Demonstrated in vivo effect

C12N2760/18088

for redistribution

C12N2760/18111

Avulavirus, e.g. Newcastle disease virus

C12N2760/18121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18123

Virus like particles [VLP]

C12N2760/18131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18141

Use of virus, viral particle or viral elements as a vector

C12N2760/18142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18143

viral genome or elements thereof as genetic vector

C12N2760/18144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/18145

Special targeting system for viral vectors

C12N2760/18151

Methods of production or purification of viral material

C12N2760/18152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18161

Methods of inactivation or attenuation

C12N2760/18162

by genetic engineering

C12N2760/18163

by chemical treatment

C12N2760/18164

by serial passage

C12N2760/18171

Demonstrated in vivo effect

C12N2760/18188

for redistribution

C12N2760/18211

Henipavirus, e.g. hendra virus

C12N2760/18221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18223

Virus like particles [VLP]

C12N2760/18231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18241

Use of virus, viral particle or viral elements as a vector

C12N2760/18242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18243

viral genome or elements thereof as genetic vector

C12N2760/18244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/18245

Special targeting system for viral vectors

C12N2760/18251

Methods of production or purification of viral material

C12N2760/18252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18261

Methods of inactivation or attenuation

C12N2760/18262

by genetic engineering

C12N2760/18263

by chemical treatment

C12N2760/18264

by serial passage

C12N2760/18271

Demonstrated in vivo effect

C12N2760/18288

for redistribution

C12N2760/18311

Metapneumovirus, e.g. avian pneumovirus

C12N2760/18321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18323

Virus like particles [VLP]

C12N2760/18331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18341

Use of virus, viral particle or viral elements as a vector

C12N2760/18342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18343

viral genome or elements thereof as genetic vector

C12N2760/18344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/18345

Special targeting system for viral vectors

C12N2760/18351

Methods of production or purification of viral material

C12N2760/18352

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18361

Methods of inactivation or attenuation

C12N2760/18362

by genetic engineering

C12N2760/18363

by chemical treatment

C12N2760/18364

by serial passage

C12N2760/18371

Demonstrated in vivo effect

C12N2760/18388

for redistribution

C12N2760/18411

Morbillivirus, e.g. Measles virus, canine distemper

C12N2760/18421

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18422

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18423

Virus like particles [VLP]

C12N2760/18431

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18432

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18433

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18434

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18441

Use of virus, viral particle or viral elements as a vector

C12N2760/18442

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18443

viral genome or elements thereof as genetic vector

C12N2760/18444

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/18445

Special targeting system for viral vectors

C12N2760/18451

Methods of production or purification of viral material

C12N2760/18452

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18461

Methods of inactivation or attenuation

C12N2760/18462

by genetic engineering

C12N2760/18463

by chemical treatment

C12N2760/18464

by serial passage

C12N2760/18471

Demonstrated in vivo effect

C12N2760/18488

For redistribution

C12N2760/18511

Pneumovirus, e.g. human respiratory syncytial virus

C12N2760/18521

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18522

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18523

Virus like particles [VLP]

C12N2760/18531

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18532

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18533

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18534

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18541

Use of virus, viral particle or viral elements as a vector

C12N2760/18542

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18543

viral genome or elements thereof as genetic vector

C12N2760/18544

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/18545

Special targeting system for viral vectors

C12N2760/18551

Methods of production or purification of viral material

C12N2760/18552

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18561

Methods of inactivation or attenuation

C12N2760/18562

by genetic engineering

C12N2760/18563

by chemical treatment

C12N2760/18564

by serial passage

C12N2760/18571

Demonstrated in vivo effect

C12N2760/18588

for redistribution

C12N2760/18611

Respirovirus, e.g. Bovine, human parainfluenza 1,3

C12N2760/18621

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18622

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18623

Virus like particles [VLP]

C12N2760/18631

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18632

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18633

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18634

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18641

Use of virus, viral particle or viral elements as a vector

C12N2760/18642

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18643

viral genome or elements thereof as genetic vector

C12N2760/18644

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/18645

Special targeting system for viral vectors

C12N2760/18651

Methods of production or purification of viral material

C12N2760/18652

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18661

Methods of inactivation or attenuation

C12N2760/18662

by genetic engineering

C12N2760/18663

by chemical treatment

C12N2760/18664

by serial passage

C12N2760/18671

Demonstrated in vivo effect

C12N2760/18688

for redistribution

C12N2760/18711

Rubulavirus, e.g. mumps virus, parainfluenza 2,4

C12N2760/18721

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18722

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18723

Virus like particles [VLP]

C12N2760/18731

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18732

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18733

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18734

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18741

Use of virus, viral particle or viral elements as a vector

C12N2760/18742

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18743

viral genome or elements thereof as genetic vector

C12N2760/18744

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/18745

Special targeting system for viral vectors

C12N2760/18751

Methods of production or purification of viral material

C12N2760/18752

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18761

Methods of inactivation or attenuation

C12N2760/18762

by genetic engineering

C12N2760/18763

by chemical treatment

C12N2760/18764

by serial passage

C12N2760/18771

Demonstrated in vivo effect

C12N2760/18788

for redistribution

C12N2760/18811

Sendai virus

C12N2760/18821

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/18822

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/18823

Virus like particles [VLP]

C12N2760/18831

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/18832

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/18833

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/18834

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/18841

Use of virus, viral particle or viral elements as a vector

C12N2760/18842

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/18843

viral genome or elements thereof as genetic vector

C12N2760/18845

Special targeting system for viral vectors

C12N2760/18851

Methods of production or purification of viral material

C12N2760/18852

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/18861

Methods of inactivation or attenuation

C12N2760/18862

by genetic engineering

C12N2760/18863

by chemical treatment

C12N2760/18864

by serial passage

C12N2760/18871

Demonstrated in vivo effect

C12N2760/18888

for redistribution

C12N2760/20011

Rhabdoviridae

C12N2760/20021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/20022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/20023

Virus like particles [VLP]

C12N2760/20031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/20032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/20033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/20034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/20041

Use of virus, viral particle or viral elements as a vector

C12N2760/20042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/20043

viral genome or elements thereof as genetic vector

C12N2760/20044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/20045

Special targeting system for viral vectors

C12N2760/20051

Methods of production or purification of viral material

C12N2760/20052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/20061

Methods of inactivation or attenuation

C12N2760/20062

by genetic engineering

C12N2760/20063

by chemical treatment

C12N2760/20064

by serial passage

C12N2760/20071

Demonstrated in vivo effect

C12N2760/20088

for redistribution

C12N2760/20111

Lyssavirus, e.g. rabies virus

C12N2760/20121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/20122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/20123

Virus like particles [VLP]

C12N2760/20131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/20132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/20133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/20134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/20141

Use of virus, viral particle or viral elements as a vector

C12N2760/20142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/20143

viral genome or elements thereof as genetic vector

C12N2760/20144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/20145

Special targeting system for viral vectors

C12N2760/20151

Methods of production or purification of viral material

C12N2760/20152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/20161

Methods of inactivation or attenuation

C12N2760/20162

by genetic engineering

C12N2760/20163

by chemical treatment

C12N2760/20164

by serial passage

C12N2760/20171

Demonstrated in vivo effect

C12N2760/20188

for redistribution

C12N2760/20211

Vesiculovirus, e.g. vesicular stomatitis Indiana virus

C12N2760/20221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2760/20222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2760/20223

Virus like particles [VLP]

C12N2760/20231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2760/20232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2760/20233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2760/20234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2760/20241

Use of virus, viral particle or viral elements as a vector

C12N2760/20242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2760/20243

viral genome or elements thereof as genetic vector

C12N2760/20244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2760/20245

Special targeting system for viral vectors

C12N2760/20251

Methods of production or purification of viral material

C12N2760/20252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2760/20261

Methods of inactivation or attenuation

C12N2760/20262

by genetic engineering

C12N2760/20263

by chemical treatment

C12N2760/20264

by serial passage

C12N2760/20271

Demonstrated in vivo effect

C12N2760/20288

for redistribution

C12N2770/00

ssRNA viruses positive-sense

C12N2770/00011

Details

C12N2770/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/00023

Virus like particles [VLP]

C12N2770/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/00041

Use of virus, viral particle or viral elements as a vector

C12N2770/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/00043

viral genome or elements thereof as genetic vector

C12N2770/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/00045

Special targeting system for viral vectors

C12N2770/00051

Methods of production or purification of viral material

C12N2770/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/00061

Methods of inactivation or attenuation

C12N2770/00062

by genetic engineering

C12N2770/00063

by chemical treatment

C12N2770/00064

by serial passage

C12N2770/00071

Demonstrated in vivo effect

C12N2770/00088

for redistribution

C12N2770/10011

Arteriviridae

C12N2770/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/10023

Virus like particles [VLP]

C12N2770/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/10041

Use of virus, viral particle or viral elements as a vector

C12N2770/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/10043

viral genome or elements thereof as genetic vector

C12N2770/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/10045

Special targeting system for viral vectors

C12N2770/10051

Methods of production or purification of viral material

C12N2770/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/10061

Methods of inactivation or attenuation

C12N2770/10062

by genetic engineering

C12N2770/10063

by chemical treatment

C12N2770/10064

by serial passage

C12N2770/10071

Demonstrated in vivo effect

C12N2770/10088

for redistribution

C12N2770/12011

Astroviridae

C12N2770/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/12023

Virus like particles [VLP]

C12N2770/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/12041

Use of virus, viral particle or viral elements as a vector

C12N2770/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/12043

viral genome or elements thereof as genetic vector

C12N2770/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/12045

Special targeting system for viral vectors

C12N2770/12051

Methods of production or purification of viral material

C12N2770/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/12061

Methods of inactivation or attenuation

C12N2770/12062

by genetic engineering

C12N2770/12063

by chemical treatment

C12N2770/12064

by serial passage

C12N2770/12071

Demonstrated in vivo effect

C12N2770/12088

for redistribution

C12N2770/14011

Bromoviridae

C12N2770/14021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/14022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/14023

Virus like particles [VLP]

C12N2770/14031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/14032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/14033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/14034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/14041

Use of virus, viral particle or viral elements as a vector

C12N2770/14042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/14043

viral genome or elements thereof as genetic vector

C12N2770/14044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/14045

Special targeting system for viral vectors

C12N2770/14051

Methods of production or purification of viral material

C12N2770/14052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/14061

Methods of inactivation or attenuation

C12N2770/14062

by genetic engineering

C12N2770/14063

by chemical treatment

C12N2770/14064

by serial passage

C12N2770/14071

Demonstrated in vivo effect

C12N2770/14088

for redistribution

C12N2770/16011

Caliciviridae

C12N2770/16021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/16022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/16023

Virus like particles [VLP]

C12N2770/16031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/16032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/16033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/16034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/16041

Use of virus, viral particle or viral elements as a vector

C12N2770/16042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/16043

viral genome or elements thereof as genetic vector

C12N2770/16044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/16045

Special targeting system for viral vectors

C12N2770/16051

Methods of production or purification of viral material

C12N2770/16052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/16061

Methods of inactivation or attenuation

C12N2770/16062

by genetic engineering

C12N2770/16063

by chemical treatment

C12N2770/16064

by serial passage

C12N2770/16071

Demonstrated in vivo effect

C12N2770/16088

for redistribution

C12N2770/18011

Comoviridae

C12N2770/18021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/18022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/18023

Virus like particles [VLP]

C12N2770/18031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/18032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/18033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/18034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/18041

Use of virus, viral particle or viral elements as a vector

C12N2770/18042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/18043

viral genome or elements thereof as genetic vector

C12N2770/18044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/18045

Special targeting system for viral vectors

C12N2770/18051

Methods of production or purification of viral material

C12N2770/18052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/18061

Methods of inactivation or attenuation

C12N2770/18062

by genetic engineering

C12N2770/18063

by chemical treatment

C12N2770/18064

by serial passage

C12N2770/18071

Demonstrated in vivo effect

C12N2770/18088

for redistribution

C12N2770/20011

Coronaviridae

C12N2770/20021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/20022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/20023

Virus like particles [VLP]

C12N2770/20031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/20032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/20033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/20034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/20041

Use of virus, viral particle or viral elements as a vector

C12N2770/20042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/20043

viral genome or elements thereof as genetic vector

C12N2770/20044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/20045

Special targeting system for viral vectors

C12N2770/20051

Methods of production or purification of viral material

C12N2770/20052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/20061

Methods of inactivation or attenuation

C12N2770/20062

by genetic engineering

C12N2770/20063

by chemical treatment

C12N2770/20064

by serial passage

C12N2770/20071

Demonstrated in vivo effect

C12N2770/20088

for redistribution

C12N2770/22011

Dicistroviridae

C12N2770/22021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/22022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/22023

Virus like particles [VLP]

C12N2770/22031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/22032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/22033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/22034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/22041

Use of virus, viral particle or viral elements as a vector

C12N2770/22042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/22043

viral genome or elements thereof as genetic vector

C12N2770/22044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/22045

Special targeting system for viral vectors

C12N2770/22051

Methods of production or purification of viral material

C12N2770/22052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/22061

Methods of inactivation or attenuation

C12N2770/22062

by genetic engineering

C12N2770/22063

by chemical treatment

C12N2770/22064

by serial passage

C12N2770/22071

Demonstrated in vivo effect

C12N2770/22088

for redistribution

C12N2770/24011

Flaviviridae

C12N2770/24021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/24022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/24023

Virus like particles [VLP]

C12N2770/24031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/24032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/24033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/24034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/24041

Use of virus, viral particle or viral elements as a vector

C12N2770/24042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/24043

viral genome or elements thereof as genetic vector

C12N2770/24044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/24045

Special targeting system for viral vectors

C12N2770/24051

Methods of production or purification of viral material

C12N2770/24052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/24061

Methods of inactivation or attenuation

C12N2770/24062

by genetic engineering

C12N2770/24063

by chemical treatment

C12N2770/24064

by serial passage

C12N2770/24071

Demonstrated in vivo effect

C12N2770/24088

for redistribution

C12N2770/24111

Flavivirus, e.g. yellow fever virus, dengue, JEV

C12N2770/24121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/24122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/24123

Virus like particles [VLP]

C12N2770/24131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/24132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/24133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/24134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/24141

Use of virus, viral particle or viral elements as a vector

C12N2770/24142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/24143

viral genome or elements thereof as genetic vector

C12N2770/24144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/24145

Special targeting system for viral vectors

C12N2770/24151

Methods of production or purification of viral material

C12N2770/24152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/24161

Methods of inactivation or attenuation

C12N2770/24162

by genetic engineering

C12N2770/24163

by chemical treatment

C12N2770/24164

by serial passage

C12N2770/24171

Demonstrated in vivo effect

C12N2770/24188

for redistribution

C12N2770/24211

Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

C12N2770/24221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/24222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/24223

Virus like particles [VLP]

C12N2770/24231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/24232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/24233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/24234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/24241

Use of virus, viral particle or viral elements as a vector

C12N2770/24242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/24243

viral genome or elements thereof as genetic vector

C12N2770/24244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/24245

Special targeting system for viral vectors

C12N2770/24251

Methods of production or purification of viral material

C12N2770/24252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/24261

Methods of inactivation or attenuation

C12N2770/24262

by genetic engineering

C12N2770/24263

by chemical treatment

C12N2770/24264

by serial passage

C12N2770/24271

Demonstrated in vivo effect

C12N2770/24288

for redistribution

C12N2770/24311

Pestivirus, e.g. bovine viral diarrhea virus

C12N2770/24321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/24322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/24323

Virus like particles [VLP]

C12N2770/24331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/24332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/24333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/24334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/24341

Use of virus, viral particle or viral elements as a vector

C12N2770/24342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/24343

viral genome or elements thereof as genetic vector

C12N2770/24344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/24345

Special targeting system for viral vectors

C12N2770/24351

Methods of production or purification of viral material

C12N2770/24352

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/24361

Methods of inactivation or attenuation

C12N2770/24362

by genetic engineering

C12N2770/24363

by chemical treatment

C12N2770/24364

by serial passage

C12N2770/24371

Demonstrated in vivo effect

C12N2770/24388

for redistribution

C12N2770/26011

Flexiviridae

C12N2770/26021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/26022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/26023

Virus like particles [VLP]

C12N2770/26031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/26032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/26033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/26034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/26041

Use of virus, viral particle or viral elements as a vector

C12N2770/26042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/26043

viral genome or elements thereof as genetic vector

C12N2770/26044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/26045

Special targeting system for viral vectors

C12N2770/26051

Methods of production or purification of viral material

C12N2770/26052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/26061

Methods of inactivation or attenuation

C12N2770/26062

by genetic engineering

C12N2770/26063

by chemical treatment

C12N2770/26064

by serial passage

C12N2770/26071

Demonstrated in vivo effect

C12N2770/26088

for redistribution

C12N2770/28011

Hepeviridae

C12N2770/28021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/28022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/28023

Virus like particles [VLP]

C12N2770/28031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/28032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/28033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/28034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/28041

Use of virus, viral particle or viral elements as a vector

C12N2770/28042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/28043

viral genome or elements thereof as genetic vector

C12N2770/28044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/28045

Special targeting system for viral vectors

C12N2770/28051

Methods of production or purification of viral material

C12N2770/28052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/28061

Methods of inactivation or attenuation

C12N2770/28062

by genetic engineering

C12N2770/28063

by chemical treatment

C12N2770/28064

by serial passage

C12N2770/28071

Demonstrated in vivo effect

C12N2770/28088

for redistribution

C12N2770/28111

Hepevirus, e.g. hepatitis E virus

C12N2770/28121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/28122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/28123

Virus like particles [VLP]

C12N2770/28131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/28132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/28133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/28134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/28141

Use of virus, viral particle or viral elements as a vector

C12N2770/28142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/28143

viral genome or elements thereof as genetic vector

C12N2770/28144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/28145

Special targeting system for viral vectors

C12N2770/28151

Methods of production or purification of viral material

C12N2770/28152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/28161

Methods of inactivation or attenuation

C12N2770/28162

by genetic engineering

C12N2770/28163

by chemical treatment

C12N2770/28164

by serial passage

C12N2770/28171

Demonstrated in vivo effect

C12N2770/28188

for redistribution

C12N2770/30011

Nodaviridae

C12N2770/30021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/30022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/30023

Virus like particles [VLP]

C12N2770/30031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/30032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/30033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/30034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/30041

Use of virus, viral particle or viral elements as a vector

C12N2770/30042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/30043

viral genome or elements thereof as genetic vector

C12N2770/30044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/30045

Special targeting system for viral vectors

C12N2770/30051

Methods of production or purification of viral material

C12N2770/30052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/30061

Methods of inactivation or attenuation

C12N2770/30062

by genetic engineering

C12N2770/30063

by chemical treatment

C12N2770/30064

by serial passage

C12N2770/30071

Demonstrated in vivo effect

C12N2770/30088

for redistribution

C12N2770/32011

Picornaviridae

C12N2770/32021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/32022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/32023

Virus like particles [VLP]

C12N2770/32031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/32032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/32033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/32034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/32041

Use of virus, viral particle or viral elements as a vector

C12N2770/32042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/32043

viral genome or elements thereof as genetic vector

C12N2770/32044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/32045

Special targeting system for viral vectors

C12N2770/32051

Methods of production or purification of viral material

C12N2770/32052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/32061

Methods of inactivation or attenuation

C12N2770/32062

by genetic engineering

C12N2770/32063

by chemical treatment

C12N2770/32064

by serial passage

C12N2770/32071

Demonstrated in vivo effect

C12N2770/32088

for redistribution

C12N2770/32111

Aphthovirus, e.g. footandmouth disease virus

C12N2770/32121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/32122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/32123

Virus like particles [VLP]

C12N2770/32131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/32132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/32133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/32134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/32141

Use of virus, viral particle or viral elements as a vector

C12N2770/32142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/32143

viral genome or elements thereof as genetic vector

C12N2770/32144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/32145

Special targeting system for viral vectors

C12N2770/32151

Methods of production or purification of viral material

C12N2770/32152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/32161

Methods of inactivation or attenuation

C12N2770/32162

by genetic engineering

C12N2770/32163

by chemical treatment

C12N2770/32164

by serial passage

C12N2770/32171

Demonstrated in vivo effect

C12N2770/32188

for redistribution

C12N2770/32211

Cardiovirus, e.g. encephalomyocarditis virus

C12N2770/32221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/32222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/32223

Virus like particles [VLP]

C12N2770/32231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/32232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/32233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/32234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/32241

Use of virus, viral particle or viral elements as a vector

C12N2770/32242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/32243

viral genome or elements thereof as genetic vector

C12N2770/32244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/32245

Special targeting system for viral vectors

C12N2770/32251

Methods of production or purification of viral material

C12N2770/32252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/32261

Methods of inactivation or attenuation

C12N2770/32262

by genetic engineering

C12N2770/32263

by chemical treatment

C12N2770/32264

by serial passage

C12N2770/32271

Demonstrated in vivo effect

C12N2770/32288

for redistribution

C12N2770/32311

Enterovirus

C12N2770/32321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/32322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/32323

Virus like particles [VLP]

C12N2770/32331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/32332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/32333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/32334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/32341

Use of virus, viral particle or viral elements as a vector

C12N2770/32342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/32343

viral genome or elements thereof as genetic vector

C12N2770/32344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/32345

Special targeting system for viral vectors

C12N2770/32351

Methods of production or purification of viral material

C12N2770/32352

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/32361

Methods of inactivation or attenuation

C12N2770/32362

by genetic engineering

C12N2770/32363

by chemical treatment

C12N2770/32364

by serial passage

C12N2770/32371

Demonstrated in vivo effect

C12N2770/32388

for redistribution

C12N2770/32411

Hepatovirus, i.e. hepatitis A virus

C12N2770/32421

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/32422

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/32423

Virus like particles [VLP]

C12N2770/32431

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/32432

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/32433

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/32434

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/32441

Use of virus, viral particle or viral elements as a vector

C12N2770/32442

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/32443

viral genome or elements thereof as genetic vector

C12N2770/32444

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/32445

Special targeting system for viral vectors

C12N2770/32451

Methods of production or purification of viral material

C12N2770/32452

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/32461

Methods of inactivation or attenuation

C12N2770/32462

by genetic engineering

C12N2770/32463

by chemical treatment

C12N2770/32464

by serial passage

C12N2770/32471

Demonstrated in vivo effect

C12N2770/32488

for redistribution

C12N2770/32511

Parechovirus, e.g. human parechovirus

C12N2770/32521

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/32522

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/32523

Virus like particles [VLP]

C12N2770/32531

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/32532

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/32533

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/32534

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/32541

Use of virus, viral particle or viral elements as a vector

C12N2770/32542

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/32543

viral genome or elements thereof as genetic vector

C12N2770/32544

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/32545

Special targeting system for viral vectors

C12N2770/32551

Methods of production or purification of viral material

C12N2770/32552

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/32561

Methods of inactivation or attenuation

C12N2770/32562

by genetic engineering

C12N2770/32563

by chemical treatment

C12N2770/32564

by serial passage

C12N2770/32571

Demonstrated in vivo effect

C12N2770/32588

for redistribution

C12N2770/32611

Poliovirus

C12N2770/32621

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/32622

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/32623

Virus like particles [VLP]

C12N2770/32631

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/32632

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/32633

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/32634

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/32641

Use of virus, viral particle or viral elements as a vector

C12N2770/32642

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/32643

viral genome or elements thereof as genetic vector

C12N2770/32644

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/32645

Special targeting system for viral vectors

C12N2770/32651

Methods of production or purification of viral material

C12N2770/32652

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/32661

Methods of inactivation or attenuation

C12N2770/32662

by genetic engineering

C12N2770/32663

by chemical treatment

C12N2770/32664

by serial passage

C12N2770/32671

Demonstrated in vivo effect

C12N2770/32688

for redistribution

C12N2770/32711

Rhinovirus

C12N2770/32721

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/32722

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/32723

Virus like particles [VLP]

C12N2770/32731

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/32732

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/32733

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/32734

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/32741

Use of virus, viral particle or viral elements as a vector

C12N2770/32742

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/32743

viral genome or elements thereof as genetic vector

C12N2770/32744

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/32745

Special targeting system for viral vectors

C12N2770/32751

Methods of production or purification of viral material

C12N2770/32752

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/32761

Methods of inactivation or attenuation

C12N2770/32762

by genetic engineering

C12N2770/32763

by chemical treatment

C12N2770/32764

by serial passage

C12N2770/32771

Demonstrated in vivo effect

C12N2770/32788

for redistribution

C12N2770/34011

Potyviridae

C12N2770/34021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/34022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/34023

Virus like particles [VLP]

C12N2770/34031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/34032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/34033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/34034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/34041

Use of virus, viral particle or viral elements as a vector

C12N2770/34042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/34043

viral genome or elements thereof as genetic vector

C12N2770/34044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/34045

Special targeting system for viral vectors

C12N2770/34051

Methods of production or purification of viral material

C12N2770/34052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/34061

Methods of inactivation or attenuation

C12N2770/34062

by genetic engineering

C12N2770/34063

by chemical treatment

C12N2770/34064

by serial passage

C12N2770/34071

Demonstrated in vivo effect

C12N2770/34088

for redistribution

C12N2770/36011

Togaviridae

C12N2770/36021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/36022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/36023

Virus like particles [VLP]

C12N2770/36031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/36032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/36033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/36034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/36041

Use of virus, viral particle or viral elements as a vector

C12N2770/36042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/36043

viral genome or elements thereof as genetic vector

C12N2770/36044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/36045

Special targeting system for viral vectors

C12N2770/36051

Methods of production or purification of viral material

C12N2770/36052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/36061

Methods of inactivation or attenuation

C12N2770/36062

by genetic engineering

C12N2770/36063

by chemical treatment

C12N2770/36064

by serial passage

C12N2770/36071

Demonstrated in vivo effect

C12N2770/36088

for redistribution

C12N2770/36111

Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

C12N2770/36121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/36122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/36123

Virus like particles [VLP]

C12N2770/36131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/36132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/36133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/36134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/36141

Use of virus, viral particle or viral elements as a vector

C12N2770/36142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/36143

viral genome or elements thereof as genetic vector

C12N2770/36144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/36145

Special targeting system for viral vectors

C12N2770/36151

Methods of production or purification of viral material

C12N2770/36152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/36161

Methods of inactivation or attenuation

C12N2770/36162

by genetic engineering

C12N2770/36163

by chemical treatment

C12N2770/36164

by serial passage

C12N2770/36171

Demonstrated in vivo effect

C12N2770/36188

for redistribution

C12N2770/36211

Rubivirus, e.g. rubella virus

C12N2770/36221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/36222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/36223

Virus like particles [VLP]

C12N2770/36231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/36232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/36233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/36234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/36241

Use of virus, viral particle or viral elements as a vector

C12N2770/36242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/36243

viral genome or elements thereof as genetic vector

C12N2770/36244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/36245

Special targeting system for viral vectors

C12N2770/36251

Methods of production or purification of viral material

C12N2770/36252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/36261

Methods of inactivation or attenuation

C12N2770/36262

by genetic engineering

C12N2770/36263

by chemical treatment

C12N2770/36264

by serial passage

C12N2770/36271

Demonstrated in vivo effect

C12N2770/36288

for redistribution

C12N2770/38011

Tombusviridae

C12N2770/38021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/38022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/38023

Virus like particles [VLP]

C12N2770/38031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/38032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/38033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/38034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/38041

Use of virus, viral particle or viral elements as a vector

C12N2770/38042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/38043

viral genome or elements thereof as genetic vector

C12N2770/38044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/38045

Special targeting system for viral vectors

C12N2770/38051

Methods of production or purification of viral material

C12N2770/38052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/38061

Methods of inactivation or attenuation

C12N2770/38062

by genetic engineering

C12N2770/38063

by chemical treatment

C12N2770/38064

by serial passage

C12N2770/38071

Demonstrated in vivo effect

C12N2770/38088

for redistribution

C12N2770/40011

Tymoviridae

C12N2770/40021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2770/40022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2770/40023

Virus like particles [VLP]

C12N2770/40031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2770/40032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2770/40033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2770/40034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2770/40041

Use of virus, viral particle or viral elements as a vector

C12N2770/40042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2770/40043

viral genome or elements thereof as genetic vector

C12N2770/40044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2770/40045

Special targeting system for viral vectors

C12N2770/40051

Methods of production or purification of viral material

C12N2770/40052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2770/40061

Methods of inactivation or attenuation

C12N2770/40062

by genetic engineering

C12N2770/40063

by chemical treatment

C12N2770/40064

by serial passage

C12N2770/40071

Demonstrated in vivo effect

C12N2770/40088

for redistribution

C12N2780/00

Naked RNA viruses

C12N2780/00011

Details

C12N2780/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2780/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2780/00023

Virus like particles [VLP]

C12N2780/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2780/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2780/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2780/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2780/00041

Use of virus, viral particle or viral elements as a vector

C12N2780/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2780/00043

viral genome or elements thereof as genetic vector

C12N2780/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2780/00045

Special targeting system for viral vectors

C12N2780/00051

Methods of production or purification of viral material

C12N2780/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2780/00061

Methods of inactivation or attenuation

C12N2780/00062

by genetic engineering

C12N2780/00063

by chemical treatment

C12N2780/00064

by serial passage

C12N2780/00071

Demonstrated in vivo effect

C12N2780/00088

for redistribution

C12N2780/10011

Narnaviridae

C12N2780/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2780/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2780/10023

Virus like particles [VLP]

C12N2780/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2780/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2780/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2780/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2780/10041

Use of virus, viral particle or viral elements as a vector

C12N2780/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2780/10043

viral genome or elements thereof as genetic vector

C12N2780/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2780/10045

Special targeting system for viral vectors

C12N2780/10051

Methods of production or purification of viral material

C12N2780/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2780/10061

Methods of inactivation or attenuation

C12N2780/10062

by genetic engineering

C12N2780/10063

by chemical treatment

C12N2780/10064

by serial passage

C12N2780/10071

Demonstrated in vivo effect

C12N2780/10088

for redistribution

C12N2790/00

Viroids or subviral agents

C12N2790/00011

Details

C12N2790/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2790/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2790/00023

Virus like particles [VLP]

C12N2790/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2790/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2790/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2790/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2790/00041

Use of virus, viral particle or viral elements as a vector

C12N2790/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2790/00043

viral genome or elements thereof as genetic vector

C12N2790/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2790/00045

Special targeting system for viral vectors

C12N2790/00051

Methods of production or purification of viral material

C12N2790/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2790/00061

Methods of inactivation or attenuation

C12N2790/00062

by genetic engineering

C12N2790/00063

by chemical treatment

C12N2790/00064

by serial passage

C12N2790/00071

Demonstrated in vivo effect

C12N2790/00088

for redistribution

C12N2790/10011

Prions

C12N2790/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2790/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2790/10023

Virus like particles [VLP]

C12N2790/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2790/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2790/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2790/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2790/10041

Use of virus, viral particle or viral elements as a vector

C12N2790/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2790/10043

viral genome or elements thereof as genetic vector

C12N2790/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2790/10045

Special targeting system for viral vectors

C12N2790/10051

Methods of production or purification of viral material

C12N2790/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2790/10061

Methods of inactivation or attenuation

C12N2790/10062

by genetic engineering

C12N2790/10063

by chemical treatment

C12N2790/10064

by serial passage

C12N2790/10071

Demonstrated in vivo effect

C12N2790/10088

for redistribution

C12N2790/12011

Satellite viruses

C12N2790/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2790/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2790/12023

Virus like particles [VLP]

C12N2790/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2790/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2790/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2790/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2790/12041

Use of virus, viral particle or viral elements as a vector

C12N2790/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2790/12043

viral genome or elements thereof as genetic vector

C12N2790/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2790/12045

Special targeting system for viral vectors

C12N2790/12051

Methods of production or purification of viral material

C12N2790/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2790/12061

Methods of inactivation or attenuation

C12N2790/12062

by genetic engineering

C12N2790/12063

by chemical treatment

C12N2790/12064

by serial passage

C12N2790/12071

Demonstrated in vivo effect

C12N2790/12088

for redistribution

C12N2790/14011

Viroids

C12N2790/14021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2790/14022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2790/14023

Virus like particles [VLP]

C12N2790/14031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2790/14032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2790/14033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2790/14034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2790/14041

Use of virus, viral particle or viral elements as a vector

C12N2790/14042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2790/14043

viral genome or elements thereof as genetic vector

C12N2790/14044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2790/14045

Special targeting system for viral vectors

C12N2790/14051

Methods of production or purification of viral material

C12N2790/14052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2790/14061

Methods of inactivation or attenuation

C12N2790/14062

by genetic engineering

C12N2790/14063

by chemical treatment

C12N2790/14064

by serial passage

C12N2790/14071

Demonstrated in vivo effect

C12N2790/14088

for redistribution

C12N2792/00

Archaeabacteria viruses

C12N2792/00011

Details

C12N2792/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2792/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2792/00023

Virus like particles [VLP]

C12N2792/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2792/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2792/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2792/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2792/00041

Use of virus, viral particle or viral elements as a vector

C12N2792/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2792/00043

viral genome or elements thereof as genetic vector

C12N2792/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2792/00045

Special targeting system for viral vectors

C12N2792/00051

Methods of production or purification of viral material

C12N2792/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2792/00061

Methods of inactivation or attenuation

C12N2792/00062

by genetic engineering

C12N2792/00063

by chemical treatment

C12N2792/00064

by serial passage

C12N2792/00071

Demonstrated in vivo effect

C12N2792/00088

for redistribution

C12N2792/10011

Fuselloviridae

C12N2792/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2792/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2792/10023

Virus like particles [VLP]

C12N2792/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2792/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2792/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2792/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2792/10041

Use of virus, viral particle or viral elements as a vector

C12N2792/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2792/10043

viral genome or elements thereof as genetic vector

C12N2792/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2792/10045

Special targeting system for viral vectors

C12N2792/10051

Methods of production or purification of viral material

C12N2792/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2792/10061

Methods of inactivation or attenuation

C12N2792/10062

by genetic engineering

C12N2792/10063

by chemical treatment

C12N2792/10064

by serial passage

C12N2792/10071

Demonstrated in vivo effect

C12N2792/10088

for redistribution

C12N2792/12011

Guttaviridae

C12N2792/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2792/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2792/12023

Virus like particles [VLP]

C12N2792/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2792/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2792/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2792/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2792/12041

Use of virus, viral particle or viral elements as a vector

C12N2792/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2792/12043

viral genome or elements thereof as genetic vector

C12N2792/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2792/12045

Special targeting system for viral vectors

C12N2792/12051

Methods of production or purification of viral material

C12N2792/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2792/12061

Methods of inactivation or attenuation

C12N2792/12062

by genetic engineering

C12N2792/12063

by chemical treatment

C12N2792/12064

by serial passage

C12N2792/12071

Demonstrated in vivo effect

C12N2792/12088

for redistribution

C12N2795/00

Bacteriophages

C12N2795/00011

Details

C12N2795/00021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/00022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/00023

Virus like particles [VLP]

C12N2795/00031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/00032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/00033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/00034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/00041

Use of virus, viral particle or viral elements as a vector

C12N2795/00042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/00043

viral genome or elements thereof as genetic vector

C12N2795/00044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/00045

Special targeting system for viral vectors

C12N2795/00051

Methods of production or purification of viral material

C12N2795/00052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/00061

Methods of inactivation or attenuation

C12N2795/00062

by genetic engineering

C12N2795/00063

by chemical treatment

C12N2795/00064

by serial passage

C12N2795/00071

Demonstrated in vivo effect

C12N2795/00088

for redistribution

C12N2795/10011

dsDNA Bacteriophages

C12N2795/10021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/10022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/10023

Virus like particles [VLP]

C12N2795/10031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/10032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/10033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/10034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/10041

Use of virus, viral particle or viral elements as a vector

C12N2795/10042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/10043

viral genome or elements thereof as genetic vector

C12N2795/10044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/10045

Special targeting system for viral vectors

C12N2795/10051

Methods of production or purification of viral material

C12N2795/10052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/10061

Methods of inactivation or attenuation

C12N2795/10062

by genetic engineering

C12N2795/10063

by chemical treatment

C12N2795/10064

by serial passage

C12N2795/10071

Demonstrated in vivo effect

C12N2795/10088

for redistribution

C12N2795/10111

Myoviridae

C12N2795/10121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/10122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/10123

Virus like particles [VLP]

C12N2795/10131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/10132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/10133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/10134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/10141

Use of virus, viral particle or viral elements as a vector

C12N2795/10142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/10143

viral genome or elements thereof as genetic vector

C12N2795/10144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/10145

Special targeting system for viral vectors

C12N2795/10151

Methods of production or purification of viral material

C12N2795/10152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/10161

Methods of inactivation or attenuation

C12N2795/10162

by genetic engineering

C12N2795/10163

by chemical treatment

C12N2795/10164

by serial passage

C12N2795/10171

Demonstrated in vivo effect

C12N2795/10188

for redistribution

C12N2795/10211

Podoviridae

C12N2795/10221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/10222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/10223

Virus like particles [VLP]

C12N2795/10231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/10232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/10233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/10234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/10241

Use of virus, viral particle or viral elements as a vector

C12N2795/10242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/10243

viral genome or elements thereof as genetic vector

C12N2795/10244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/10245

Special targeting system for viral vectors

C12N2795/10251

Methods of production or purification of viral material

C12N2795/10252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/10261

Methods of inactivation or attenuation

C12N2795/10262

by genetic engineering

C12N2795/10263

by chemical treatment

C12N2795/10264

by serial passage

C12N2795/10271

Demonstrated in vivo effect

C12N2795/10288

for redistribution

C12N2795/10311

Siphoviridae

C12N2795/10321

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/10322

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/10323

Virus like particles [VLP]

C12N2795/10331

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/10332

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/10333

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/10334

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/10341

Use of virus, viral particle or viral elements as a vector

C12N2795/10342

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/10343

viral genome or elements thereof as genetic vector

C12N2795/10344

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/10345

Special targeting system for viral vectors

C12N2795/10351

Methods of production or purification of viral material

C12N2795/10352

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/10361

Methods of inactivation or attenuation

C12N2795/10362

by genetic engineering

C12N2795/10363

by chemical treatment

C12N2795/10364

by serial passage

C12N2795/10371

Demonstrated in vivo effect

C12N2795/10388

for redistribution

C12N2795/12011

dsRNA Bacteriophages

C12N2795/12021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/12022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/12023

Virus like particles [VLP]

C12N2795/12031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/12032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/12033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/12034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/12041

Use of virus, viral particle or viral elements as a vector

C12N2795/12042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/12043

viral genome or elements thereof as genetic vector

C12N2795/12044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/12045

Special targeting system for viral vectors

C12N2795/12051

Methods of production or purification of viral material

C12N2795/12052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/12061

Methods of inactivation or attenuation

C12N2795/12062

by genetic engineering

C12N2795/12063

by chemical treatment

C12N2795/12064

by serial passage

C12N2795/12071

Demonstrated in vivo effect

C12N2795/12088

for redistribution

C12N2795/14011

ssDNA Bacteriophages

C12N2795/14021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/14022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/14023

Virus like particles [VLP]

C12N2795/14031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/14032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/14033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/14034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/14041

Use of virus, viral particle or viral elements as a vector

C12N2795/14042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/14043

viral genome or elements thereof as genetic vector

C12N2795/14044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/14045

Special targeting system for viral vectors

C12N2795/14051

Methods of production or purification of viral material

C12N2795/14052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/14061

Methods of inactivation or attenuation

C12N2795/14062

by genetic engineering

C12N2795/14063

by chemical treatment

C12N2795/14064

by serial passage

C12N2795/14071

Demonstrated in vivo effect

C12N2795/14088

for redistribution

C12N2795/14111

Inoviridae

C12N2795/14121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/14122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/14123

Virus like particles [VLP]

C12N2795/14131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/14132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/14133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/14134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/14141

Use of virus, viral particle or viral elements as a vector

C12N2795/14142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/14143

viral genome or elements thereof as genetic vector

C12N2795/14144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/14145

Special targeting system for viral vectors

C12N2795/14151

Methods of production or purification of viral material

C12N2795/14152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/14161

Methods of inactivation or attenuation

C12N2795/14162

by genetic engineering

C12N2795/14163

by chemical treatment

C12N2795/14164

by serial passage

C12N2795/14171

Demonstrated in vivo effect

C12N2795/14188

for redistribution

C12N2795/14211

Microviridae

C12N2795/14221

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/14222

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/14223

Virus like particles [VLP]

C12N2795/14231

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/14232

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/14233

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/14234

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/14241

Use of virus, viral particle or viral elements as a vector

C12N2795/14242

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/14243

viral genome or elements thereof as genetic vector

C12N2795/14244

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/14245

Special targeting system for viral vectors

C12N2795/14251

Methods of production or purification of viral material

C12N2795/14252

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/14261

Methods of inactivation or attenuation

C12N2795/14262

by genetic engineering

C12N2795/14263

by chemical treatment

C12N2795/14264

by serial passage

C12N2795/14271

Demonstrated in vivo effect

C12N2795/14288

for redistribution

C12N2795/16011

ssRNA Bacteriophages negative-sense

C12N2795/16021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/16022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/16023

Virus like particles [VLP]

C12N2795/16031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/16032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/16033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/16034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/16041

Use of virus, viral particle or viral elements as a vector

C12N2795/16042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/16043

viral genome or elements thereof as genetic vector

C12N2795/16044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/16045

Special targeting system for viral vectors

C12N2795/16051

Methods of production or purification of viral material

C12N2795/16052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/16061

Methods of inactivation or attenuation

C12N2795/16062

by genetic engineering

C12N2795/16063

by chemical treatment

C12N2795/16064

by serial passage

C12N2795/16071

Demonstrated in vivo effect

C12N2795/16088

for redistribution

C12N2795/18011

ssRNA Bacteriophages positive-sense

C12N2795/18021

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/18022

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/18023

Virus like particles [VLP]

C12N2795/18031

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/18032

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/18033

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/18034

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/18041

Use of virus, viral particle or viral elements as a vector

C12N2795/18042

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/18043

viral genome or elements thereof as genetic vector

C12N2795/18044

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/18045

Special targeting system for viral vectors

C12N2795/18051

Methods of production or purification of viral material

C12N2795/18052

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/18061

Methods of inactivation or attenuation

C12N2795/18062

by genetic engineering

C12N2795/18063

by chemical treatment

C12N2795/18064

by serial passage

C12N2795/18071

Demonstrated in vivo effect

C12N2795/18088

for redistribution

C12N2795/18111

Leviviridae

C12N2795/18121

Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N2795/18122

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N2795/18123

Virus like particles [VLP]

C12N2795/18131

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N2795/18132

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N2795/18133

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N2795/18134

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N2795/18141

Use of virus, viral particle or viral elements as a vector

C12N2795/18142

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N2795/18143

viral genome or elements thereof as genetic vector

C12N2795/18144

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N2795/18145

Special targeting system for viral vectors

C12N2795/18151

Methods of production or purification of viral material

C12N2795/18152

relating to complementing cells and packaging systems for producing virus or viral particles

C12N2795/18161

Methods of inactivation or attenuation

C12N2795/18162

by genetic engineering

C12N2795/18163

by chemical treatment

C12N2795/18164

by serial passage

C12N2795/18171

Demonstrated in vivo effect

C12N2795/18188

for redistribution

C12N2796/00

Viruses not covered by groups C12N2710/00 - C12N2795/00

C12N2799/00

Uses of viruses

From 2012-03-15 codes in the range C12N2799/00 - C12N2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N2710/00-C12N2795/00

C12N2799/02

as vector

C12N2799/021

for the expression of a heterologous nucleic acid

C12N2799/022

where the vector is derived from an adenovirus

C12N2799/023

where the vector is derived from a poxvirus

C12N2799/025

where the vector is derived from a parvovirus

C12N2799/026

where the vector is derived from a baculovirus

C12N2799/027

where the vector is derived from a retrovirus

C12N2799/028

where the vector is derived from a herpesvirus

C12N2799/04

in vivo

C12N2799/06

in vitro

C12N2800/00

Nucleic acids vectors

C12N2800/10

Plasmid DNA

C12N2800/101

for bacteria

C12N2800/102

for yeast

C12N2800/103

for invertebrates

C12N2800/105

for insects

C12N2800/106

for vertebrates

C12N2800/107

for mammalian

C12N2800/108

episomal vectors

C12N2800/20

Pseudochromosomes, minichrosomosomes

C12N2800/202

of bacteriophage origin

C12N2800/204

of bacterial origin, e.g. BAC

C12N2800/206

of yeast origin, e.g. YAC, 2u

C12N2800/208

of mammalian origin, e.g. minichromosome

C12N2800/22

Vectors comprising a coding region that has been codon optimised for expression in a respective host

C12N2800/24

Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

C12N2800/30

Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

C12N2800/40

Systems of functionally co-operating vectors

C12N2800/50

Vectors for producing vectors

C12N2800/60

Vectors containing traps for, e.g. exons, promoters

C12N2800/70

Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites

C12N2800/80

Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

C12N2800/90

Vectors containing a transposable element

C12N2800/95

Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers

C12N2810/00

Vectors comprising a targeting moiety

C12N2810/10

Vectors comprising a non-peptidic targeting moiety

C12N2810/40

Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

C12N2810/405

Vectors comprising RGD peptide

C12N2810/50

Vectors comprising as targeting moiety peptide derived from defined protein

C12N2810/55

from bacteria

C12N2810/60

from viruses

C12N2810/6009

dsDNA viruses

C12N2810/6018

Adenoviridae

C12N2810/6027

ssDNA viruses

C12N2810/6036

DNA rev transcr viruses

C12N2810/6045

RNA rev transcr viruses

C12N2810/6054

Retroviridae

C12N2810/6063

ds RNA viruses

C12N2810/6072

negative strand RNA viruses

C12N2810/6081

rhabdoviridae, e.g. VSV

C12N2810/609

positive strand RNA viruses

C12N2810/65

from plants

C12N2810/70

from fungi

C12N2810/75

from invertebrates

C12N2810/80

from vertebrates

C12N2810/85

mammalian

C12N2810/851

from growth factors

from growth regulators

C12N2810/852

from cytokines

from lymphokines

from interferons

C12N2810/853

from tumor necrosis factor, TNF

C12N2810/854

from hormones

C12N2810/855

from receptors

from cell surface antigens

from cell surface determinants

C12N2810/856

from integrins

C12N2810/857

from blood coagulation or fibrinolysis factors

C12N2810/858

from apolipopeptides

C12N2810/859

from immunoglobulins

C12N2810/90

avian

C12N2820/00

Vectors comprising a special origin of replication system

C12N2820/002

inducible or controllable

C12N2820/005

cell-cycle regulated

C12N2820/007

tissue or cell-specific

C12N2820/10

multiple origins of replication

C12N2820/55

from bacteria

C12N2820/60

from viruses

C12N2820/65

from plants

C12N2820/70

from fungi

C12N2820/702

yeast

C12N2820/704

S. cerevisae

C12N2820/706

S. pombe

C12N2820/708

C. albicans

C12N2820/75

from invertebrates

C12N2820/80

from vertebrates

C12N2820/85

mammalian

C12N2820/90

avian

C12N2830/00

Vector systems having a special element relevant for transcription

C12N2830/001

controllable enhancer/promoter combination

C12N2830/002

inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

C12N2830/003

tet inducible

C12N2830/005

repressible enhancer/promoter combination, e.g. KRAB

C12N2830/006

tet repressible

C12N2830/007

cell cycle specific enhancer/promoter combination

C12N2830/008

cell type or tissue specific enhancer/promoter combination

C12N2830/15

chimeric enhancer/promoter combination

C12N2830/20

transcription of more than one cistron

C12N2830/205

bidirectional

C12N2830/30

being an enhancer not forming part of the promoter region

C12N2830/32

being an silencer not forming part of the promoter region

C12N2830/34

being a transcription initiation element

C12N2830/36

being a transcription termination element

C12N2830/38

being a stuffer

C12N2830/40

being an insulator

C12N2830/42

being an intron or intervening sequence for splicing and/or stability of RNA

C12N2830/46

elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

C12N2830/48

regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

C12N2830/50

regulating RNA stability, not being an intron, e.g. poly A signal

C12N2830/52

encoding ribozyme for self-inactivation

C12N2830/55

from bacteria

C12N2830/60

from viruses

C12N2830/65

from plants

C12N2830/70

from fungi

C12N2830/702

yeast

C12N2830/704

S. cerevisiae

C12N2830/706

S. pombe

C12N2830/708

C. albicans

C12N2830/75

from invertebrates

C12N2830/80

from vertebrates

C12N2830/85

mammalian

C12N2830/90

avian

C12N2840/00

Vectors comprising a special translation-regulating system

C12N2840/002

controllable or inducible

C12N2840/005

cell cycle specific

C12N2840/007

cell or tissue specific

C12N2840/10

regulates levels of translation

C12N2840/102

inhibiting translation

C12N2840/105

enhancing translation

C12N2840/107

inhibiting translational read-through

C12N2840/20

translation of more than one cistron

C12N2840/203

having an IRES

C12N2840/206

having multiple IRES

C12N2840/44

being a specific part of the splice mechanism, e.g. donor, acceptor

C12N2840/445

for trans-splicing, e.g. polypyrimidine tract, branch point splicing

C12N2840/50

utilisation of non-ATG initiation codon

This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here

C12N2840/55

from bacteria

C12N2840/60

from viruses

C12N2840/65

from plants

C12N2840/70

from fungi

C12N2840/702

yeast

C12N2840/704

S. cerevisiae

C12N2840/706

S. pombe

C12N2840/708

C. albicans

C12N2840/75

from invertebrates

C12N2840/80

from vertebrates

C12N2840/85

mammalian

C12N2840/90

avian

C12N2999/00

Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00

This group is for classification of patent and non-patent literature documents.

When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

C12N2999/002

Adverse teaching

C12N2999/005

Biological teaching, e.g. a link between protein and disease, new virus causing pandemic

C12N2999/007

Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals